drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
sequencelengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
sequencelengths 1
10
| all_paths_str
sequencelengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00432 | DB10795 | 1,083 | 221 | [
"DDInter1868",
"DDInter1486"
] | Trifluridine | Poliovirus type 1 antigen (formaldehyde inactivated) | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity against Herpes simplex virus type 1 and 2. The combination product of trifluridine with tipiracil marketed as Lonsurf has been approved in Japan, the United States, and the European Union for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. In the anticancer therapy, trifluridine acts as a thymidine-based nucleoside metabolic inhibitor that gets | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a continuous line of monkey kidney cells. | Moderate | 1 | [
[
[
1083,
24,
221
]
],
[
[
1083,
64,
581
],
[
581,
24,
221
]
],
[
[
1083,
63,
599
],
[
599,
24,
221
]
],
[
[
1083,
24,
384
],
[
384,
24,
221
]
],
[
[
1083,
25,
1510
],
[
1510,
24,
221
]
],
[
[
1083,
75,
1064
],
[
1064,
24,
221
]
],
[
[
1083,
25,
676
],
[
676,
63,
221
]
],
[
[
1083,
40,
1238
],
[
1238,
24,
221
]
],
[
[
1083,
24,
738
],
[
738,
63,
221
]
],
[
[
1083,
64,
581
],
[
581,
25,
36
],
[
36,
24,
221
]
]
] | [
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Trifluridine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Trifluridine",
"{u} (Compound) resembles {v} (Compound)",
"Pentostatin"
],
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
]
] | Trifluridine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Trifluridine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Trifluridine (Compound) resembles Cladribine (Compound) and Trifluridine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Trifluridine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Trifluridine (Compound) resembles Pentostatin (Compound) and Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Trifluridine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) |
DB11703 | DB14783 | 405 | 287 | [
"DDInter9",
"DDInter574"
] | Acalabrutinib | Diroximel fumarate | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy. In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021. | Moderate | 1 | [
[
[
405,
24,
287
]
],
[
[
405,
63,
1101
],
[
1101,
24,
287
]
],
[
[
405,
64,
384
],
[
384,
24,
287
]
],
[
[
405,
24,
1619
],
[
1619,
24,
287
]
],
[
[
405,
25,
351
],
[
351,
24,
287
]
],
[
[
405,
64,
1510
],
[
1510,
25,
287
]
],
[
[
405,
25,
676
],
[
676,
64,
287
]
],
[
[
405,
25,
1259
],
[
1259,
25,
287
]
],
[
[
405,
63,
713
],
[
713,
25,
287
]
],
[
[
405,
63,
1101
],
[
1101,
64,
1560
],
[
1560,
24,
287
]
]
] | [
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
]
] | Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Acalabrutinib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Acalabrutinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Acalabrutinib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate
Acalabrutinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Diroximel fumarate
Acalabrutinib may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Diroximel fumarate
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may lead to a major life threatening interaction when taken with Diroximel fumarate
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate |
DB00222 | DB00397 | 245 | 1,466 | [
"DDInter825",
"DDInter1458"
] | Glimepiride | Phenylpropanolamine | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Moderate | 1 | [
[
[
245,
24,
1466
]
],
[
[
245,
63,
73
],
[
73,
25,
1466
]
],
[
[
245,
21,
28929
],
[
28929,
60,
1466
]
],
[
[
245,
24,
1178
],
[
1178,
63,
1466
]
],
[
[
245,
24,
999
],
[
999,
24,
1466
]
],
[
[
245,
40,
959
],
[
959,
63,
1466
]
],
[
[
245,
23,
1551
],
[
1551,
63,
1466
]
],
[
[
245,
63,
1245
],
[
1245,
24,
1466
]
],
[
[
245,
24,
1161
],
[
1161,
64,
1466
]
],
[
[
245,
24,
22
],
[
22,
74,
1466
]
]
] | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Glimepiride",
"{u} (Compound) causes {v} (Side Effect)",
"Confusional state"
],
[
"Confusional state",
"{u} (Side Effect) is caused by {v} (Compound)",
"Phenylpropanolamine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methyldopa"
],
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reserpine"
],
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
],
[
"Selegiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
]
] | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Phenylpropanolamine
Glimepiride (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Phenylpropanolamine (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine
Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine
Glimepiride may cause a minor interaction that can limit clinical effects when taken with Methyldopa and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Reserpine and Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Selegiline and Selegiline may lead to a major life threatening interaction when taken with Phenylpropanolamine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) resembles Phenylpropanolamine (Compound) and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine |
DB00852 | DB01136 | 1,445 | 772 | [
"DDInter1545",
"DDInter305"
] | Pseudoephedrine | Carvedilol | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseudoephedrine was described in dogs in 1927. | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension. Carvedilol was granted FDA approval on 14 September 1995. | Moderate | 1 | [
[
[
1445,
24,
772
]
],
[
[
1445,
6,
12523
],
[
12523,
45,
772
]
],
[
[
1445,
21,
29118
],
[
29118,
60,
772
]
],
[
[
1445,
63,
542
],
[
542,
23,
772
]
],
[
[
1445,
24,
1296
],
[
1296,
63,
772
]
],
[
[
1445,
24,
714
],
[
714,
24,
772
]
],
[
[
1445,
63,
1685
],
[
1685,
24,
772
]
],
[
[
1445,
1,
22
],
[
22,
63,
772
]
],
[
[
1445,
25,
1053
],
[
1053,
63,
772
]
],
[
[
1445,
24,
659
],
[
659,
64,
772
]
]
] | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Carvedilol"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Carvedilol"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Carvedilol"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) resembles {v} (Compound)",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Pseudoephedrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carvedilol"
]
]
] | Pseudoephedrine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Carvedilol (Compound)
Pseudoephedrine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Carvedilol (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Carvedilol
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Pseudoephedrine (Compound) resembles Ephedrine (Compound) and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Pseudoephedrine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may lead to a major life threatening interaction when taken with Carvedilol |
DB09078 | DB11837 | 1,228 | 1,297 | [
"DDInter1036",
"DDInter1351"
] | Lenvatinib | Osilodrostat | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013. Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. Cushing's disease), and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication. | Moderate | 1 | [
[
[
1228,
24,
1297
]
],
[
[
1228,
62,
112
],
[
112,
23,
1297
]
],
[
[
1228,
63,
623
],
[
623,
24,
1297
]
],
[
[
1228,
24,
657
],
[
657,
24,
1297
]
],
[
[
1228,
24,
971
],
[
971,
63,
1297
]
],
[
[
1228,
64,
990
],
[
990,
24,
1297
]
],
[
[
1228,
63,
876
],
[
876,
25,
1297
]
],
[
[
1228,
25,
351
],
[
351,
25,
1297
]
],
[
[
1228,
64,
347
],
[
347,
25,
1297
]
],
[
[
1228,
25,
982
],
[
982,
64,
1297
]
]
] | [
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Lenvatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osilodrostat"
]
],
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
],
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Lenvatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Lenvatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Lenvatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibutilide"
],
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Lenvatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
]
] | Lenvatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Lenvatinib may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine and Tizanidine may lead to a major life threatening interaction when taken with Osilodrostat
Lenvatinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Osilodrostat
Lenvatinib may lead to a major life threatening interaction when taken with Ibutilide and Ibutilide may lead to a major life threatening interaction when taken with Osilodrostat
Lenvatinib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Osilodrostat |
DB00761 | DB01173 | 1,621 | 358 | [
"DDInter1497",
"DDInter1349"
] | Potassium chloride | Orphenadrine | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release dosage forms and those products formulated for preparation of solution prior to ingestion. | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Major | 2 | [
[
[
1621,
25,
358
]
],
[
[
1621,
25,
211
],
[
211,
1,
358
]
],
[
[
1621,
25,
272
],
[
272,
24,
358
]
],
[
[
1621,
25,
820
],
[
820,
63,
358
]
],
[
[
1621,
64,
1164
],
[
1164,
1,
358
]
],
[
[
1621,
25,
1405
],
[
1405,
40,
358
]
],
[
[
1621,
64,
128
],
[
128,
24,
358
]
],
[
[
1621,
21,
28929
],
[
28929,
60,
358
]
],
[
[
1621,
25,
401
],
[
401,
35,
358
]
],
[
[
1621,
64,
662
],
[
662,
35,
358
]
]
] | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orphenadrine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trimipramine"
],
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Potassium chloride",
"{u} (Compound) causes {v} (Side Effect)",
"Confusional state"
],
[
"Confusional state",
"{u} (Side Effect) is caused by {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
]
] | Potassium chloride may lead to a major life threatening interaction when taken with Tolterodine and Tolterodine (Compound) resembles Orphenadrine (Compound)
Potassium chloride may lead to a major life threatening interaction when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Potassium chloride may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Potassium chloride may lead to a major life threatening interaction when taken with Trimipramine and Trimipramine (Compound) resembles Orphenadrine (Compound)
Potassium chloride may lead to a major life threatening interaction when taken with Cyclobenzaprine and Cyclobenzaprine (Compound) resembles Orphenadrine (Compound)
Potassium chloride may lead to a major life threatening interaction when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Potassium chloride (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Orphenadrine (Compound)
Potassium chloride may lead to a major life threatening interaction when taken with Promethazine and Promethazine (Compound) resembles Orphenadrine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Potassium chloride may lead to a major life threatening interaction when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Orphenadrine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine |
DB00570 | DB10583 | 147 | 949 | [
"DDInter1936",
"DDInter415"
] | Vinblastine | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium sulfate filtration and precipation. | Moderate | 1 | [
[
[
147,
24,
949
]
],
[
[
147,
63,
589
],
[
589,
24,
949
]
],
[
[
147,
24,
250
],
[
250,
24,
949
]
],
[
[
147,
25,
1377
],
[
1377,
24,
949
]
],
[
[
147,
24,
1093
],
[
1093,
63,
949
]
],
[
[
147,
62,
970
],
[
970,
24,
949
]
],
[
[
147,
25,
1259
],
[
1259,
63,
949
]
],
[
[
147,
64,
1066
],
[
1066,
24,
949
]
],
[
[
147,
23,
60
],
[
60,
24,
949
]
],
[
[
147,
63,
589
],
[
589,
25,
1377
],
[
1377,
24,
949
]
]
] | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
],
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
],
[
"Capecitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
]
] | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab and Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Vinblastine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Fluorouracil and Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Vinblastine may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Vinblastine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) |
DB08875 | DB15233 | 1,618 | 1,650 | [
"DDInter262",
"DDInter142"
] | Cabozantinib | Avapritinib | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133] | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 and EMA approval on 24 September 2020. | Major | 2 | [
[
[
1618,
25,
1650
]
],
[
[
1618,
64,
1374
],
[
1374,
24,
1650
]
],
[
[
1618,
63,
1101
],
[
1101,
24,
1650
]
],
[
[
1618,
24,
159
],
[
159,
24,
1650
]
],
[
[
1618,
25,
982
],
[
982,
24,
1650
]
],
[
[
1618,
64,
1512
],
[
1512,
25,
1650
]
],
[
[
1618,
25,
1604
],
[
1604,
25,
1650
]
],
[
[
1618,
63,
723
],
[
723,
25,
1650
]
],
[
[
1618,
24,
283
],
[
283,
25,
1650
]
],
[
[
1618,
76,
1274
],
[
1274,
37,
1650
]
]
] | [
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
]
] | Cabozantinib may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Cabozantinib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Cabozantinib may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Avapritinib
Cabozantinib may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Avapritinib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may lead to a major life threatening interaction when taken with Avapritinib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Avapritinib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Cabozantinib may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib and Flurbiprofen may lead to a major life threatening interaction when taken with Avapritinib |
DB00099 | DB01073 | 440 | 1,488 | [
"DDInter735",
"DDInter745"
] | Filgrastim | Fludarabine | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in _E. Coli_. Human G-CSF is a glycoprotein that regulates the production and release of neutrophils from the bone marrow. Filgrastim mimics the biological actions of G-CSF to increase the levels of neutrophils in the blood. It has a number of therapeutic uses, including the management and prevention of infections and febrile neutropenia in patients receiving myelosuppressive chemotherapy or radiation therapy. It is also used to manage severe chronic neutropenia and mobilize hematopoietic progenitor cells to the | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Moderate | 1 | [
[
[
440,
24,
1488
]
],
[
[
440,
24,
1426
],
[
1426,
1,
1488
]
],
[
[
440,
24,
975
],
[
975,
63,
1488
]
],
[
[
440,
24,
134
],
[
134,
24,
1488
]
],
[
[
440,
63,
491
],
[
491,
24,
1488
]
],
[
[
440,
24,
1238
],
[
1238,
25,
1488
]
],
[
[
440,
24,
1224
],
[
1224,
35,
1488
]
],
[
[
440,
25,
1064
],
[
1064,
36,
1488
]
],
[
[
440,
24,
1426
],
[
1426,
40,
11382
],
[
11382,
1,
1488
]
],
[
[
440,
24,
975
],
[
975,
63,
372
],
[
372,
1,
1488
]
]
] | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azacitidine"
],
[
"Azacitidine",
"{u} (Compound) resembles {v} (Compound)",
"Fludarabine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
],
[
"Lurbinectedin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
],
[
"Pentostatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludarabine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
],
[
"Cytarabine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Filgrastim",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Fludarabine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azacitidine"
],
[
"Azacitidine",
"{u} (Compound) resembles {v} (Compound)",
"Adenosine triphosphate"
],
[
"Adenosine triphosphate",
"{u} (Compound) resembles {v} (Compound)",
"Fludarabine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
],
[
"Lurbinectedin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} (Compound) resembles {v} (Compound)",
"Fludarabine"
]
]
] | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Azacitidine and Azacitidine (Compound) resembles Fludarabine (Compound)
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin may lead to a major life threatening interaction when taken with Fludarabine
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cytarabine (Compound) resembles Fludarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Filgrastim may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) resembles Fludarabine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Fludarabine
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Azacitidine and Azacitidine (Compound) resembles Adenosine triphosphate (Compound) and Adenosine triphosphate (Compound) resembles Fludarabine (Compound)
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) resembles Fludarabine (Compound) |
DB01229 | DB01320 | 973 | 651 | [
"DDInter1377",
"DDInter783"
] | Paclitaxel | Fosphenytoin | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. | Moderate | 1 | [
[
[
973,
24,
651
]
],
[
[
973,
62,
307
],
[
307,
1,
651
]
],
[
[
973,
63,
362
],
[
362,
1,
651
]
],
[
[
973,
6,
6017
],
[
6017,
45,
651
]
],
[
[
973,
21,
29028
],
[
29028,
60,
651
]
],
[
[
973,
63,
1347
],
[
1347,
23,
651
]
],
[
[
973,
24,
1250
],
[
1250,
63,
651
]
],
[
[
973,
63,
147
],
[
147,
24,
651
]
],
[
[
973,
25,
908
],
[
908,
63,
651
]
],
[
[
973,
64,
770
],
[
770,
24,
651
]
]
] | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Paclitaxel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} (Compound) resembles {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Paclitaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Encephalopathy"
],
[
"Encephalopathy",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
]
] | Paclitaxel may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Fosphenytoin (Compound)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Paclitaxel (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Fosphenytoin (Compound)
Paclitaxel (Compound) causes Encephalopathy (Side Effect) and Encephalopathy (Side Effect) is caused by Fosphenytoin (Compound)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Fosphenytoin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Paclitaxel may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Paclitaxel may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin |
DB00196 | DB00353 | 600 | 588 | [
"DDInter743",
"DDInter1187"
] | Fluconazole | Methylergometrine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose. | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | Moderate | 1 | [
[
[
600,
24,
588
]
],
[
[
600,
24,
826
],
[
826,
40,
588
]
],
[
[
600,
24,
628
],
[
628,
1,
588
]
],
[
[
600,
6,
8374
],
[
8374,
45,
588
]
],
[
[
600,
7,
14690
],
[
14690,
46,
588
]
],
[
[
600,
18,
6718
],
[
6718,
57,
588
]
],
[
[
600,
21,
29024
],
[
29024,
60,
588
]
],
[
[
600,
25,
1362
],
[
1362,
63,
588
]
],
[
[
600,
24,
913
],
[
913,
63,
588
]
],
[
[
600,
23,
1101
],
[
1101,
24,
588
]
]
] | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylergometrine"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ergotamine"
],
[
"Ergotamine",
"{u} (Compound) resembles {v} (Compound)",
"Methylergometrine"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ergometrine"
],
[
"Ergometrine",
"{u} (Compound) resembles {v} (Compound)",
"Methylergometrine"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Methylergometrine"
]
],
[
[
"Fluconazole",
"{u} (Compound) upregulates {v} (Gene)",
"ABHD6"
],
[
"ABHD6",
"{u} (Gene) is upregulated by {v} (Compound)",
"Methylergometrine"
]
],
[
[
"Fluconazole",
"{u} (Compound) downregulates {v} (Gene)",
"USP22"
],
[
"USP22",
"{u} (Gene) is downregulated by {v} (Compound)",
"Methylergometrine"
]
],
[
[
"Fluconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methylergometrine"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylergometrine"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylergometrine"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylergometrine"
]
]
] | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Ergotamine and Ergotamine (Compound) resembles Methylergometrine (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Ergometrine and Ergometrine (Compound) resembles Methylergometrine (Compound)
Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Methylergometrine (Compound)
Fluconazole (Compound) upregulates ABHD6 (Gene) and ABHD6 (Gene) is upregulated by Methylergometrine (Compound)
Fluconazole (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Methylergometrine (Compound)
Fluconazole (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Methylergometrine (Compound)
Fluconazole may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Methylergometrine
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Methylergometrine
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Methylergometrine |
DB01142 | DB11160 | 1,264 | 337 | [
"DDInter593",
"DDInter1459"
] | Doxepin | Phenyltoloxamine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter | Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the more common salt form that acts as an active ingredient in pharmaceutical products and promotes hay fever relief via reversing the effects of histamine. Phenyltoloxamine acts as an adjuvant analgesic, which augments the analgesic effect of acetaminophen. It also potentiates the effects of other drugs, such as codeine and codeine derivatives. Although phenyltoloxamine's ability to potentiate the effects of analgesics may be explained in part by its chemical nature as a first-generation H1 antihistamine that is capable of crossing the blood-brain barrier and causing tranquilizing effects at CNS histamine receptors, many of the drug's specific pharmacokinetics are not readily available - perhaps also because many early (phenyltoloxamine was involved in studies as early as the 1950s) first-generation antihistamines were not optimally investigated . Nevertheless, phenyltoloxamine is used to a fairly limited extent in contemporary medicine, with only very few products involving it as an active ingredient. | Moderate | 1 | [
[
[
1264,
24,
337
]
],
[
[
1264,
35,
820
],
[
820,
24,
337
]
],
[
[
1264,
63,
999
],
[
999,
24,
337
]
],
[
[
1264,
24,
1511
],
[
1511,
24,
337
]
],
[
[
1264,
74,
1376
],
[
1376,
24,
337
]
],
[
[
1264,
25,
1053
],
[
1053,
24,
337
]
],
[
[
1264,
24,
1609
],
[
1609,
63,
337
]
],
[
[
1264,
64,
1621
],
[
1621,
25,
337
]
],
[
[
1264,
35,
820
],
[
820,
23,
771
],
[
771,
62,
337
]
],
[
[
1264,
63,
999
],
[
999,
63,
1594
],
[
1594,
24,
337
]
]
] | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Doxepin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Doxepin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Doxepin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
]
] | Doxepin (Compound) resembles Alimemazine (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Doxepin (Compound) resembles Diphenhydramine (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Doxepin may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Doxepin may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Phenyltoloxamine
Doxepin (Compound) resembles Alimemazine (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Phenyltoloxamine
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine |
DB00620 | DB00808 | 175 | 1,605 | [
"DDInter1855",
"DDInter916"
] | Triamcinolone | Indapamide | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a number of lifestyle changes (ie. reduced sodium intake) along with pharmacotherapy - it should be noted that treatment with several antihypertensive agents may be required in order to achieve blood pressure targets. Thiazide-like diuretics such as indapamide are a valuable tool for the treatment of hypertension and continue to grow in popularity, falling behind only ACE inhibitors in terms of prescription frequency. When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index, lowering oxidative stress, inhibiting platelet aggregation, and reducing microalbuminuria associated with diabetes. Interestingly, unlike thiazide diuretics, several sources suggest that indapamide is not associated with glucose or lipid disturbances.[A204134,A204161] Indapamide is characterized by both a methylindoline and a sulfamoyl chlorobenzamide functional group, with the former being largely responsible for the molecule’s lipid solubility. | Moderate | 1 | [
[
[
175,
24,
1605
]
],
[
[
175,
63,
811
],
[
811,
1,
1605
]
],
[
[
175,
24,
1335
],
[
1335,
40,
1605
]
],
[
[
175,
6,
8374
],
[
8374,
45,
1605
]
],
[
[
175,
21,
29135
],
[
29135,
60,
1605
]
],
[
[
175,
24,
126
],
[
126,
23,
1605
]
],
[
[
175,
24,
761
],
[
761,
63,
1605
]
],
[
[
175,
63,
1647
],
[
1647,
24,
1605
]
],
[
[
175,
25,
593
],
[
593,
63,
1605
]
],
[
[
175,
40,
1486
],
[
1486,
63,
1605
]
]
] | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Indapamide"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} (Compound) resembles {v} (Compound)",
"Indapamide"
]
],
[
[
"Triamcinolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Indapamide"
]
],
[
[
"Triamcinolone",
"{u} (Compound) causes {v} (Side Effect)",
"Blister"
],
[
"Blister",
"{u} (Side Effect) is caused by {v} (Compound)",
"Indapamide"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indapamide"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
]
] | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Indapamide (Compound)
Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indapamide (Compound)
Triamcinolone (Compound) causes Blister (Side Effect) and Blister (Side Effect) is caused by Indapamide (Compound)
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Indapamide
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Indapamide
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Indapamide
Triamcinolone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Indapamide
Triamcinolone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Indapamide |
DB00696 | DB12267 | 826 | 1,476 | [
"DDInter665",
"DDInter233"
] | Ergotamine | Brigatinib | A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | Moderate | 1 | [
[
[
826,
24,
1476
]
],
[
[
826,
24,
629
],
[
629,
24,
1476
]
],
[
[
826,
40,
628
],
[
628,
24,
1476
]
],
[
[
826,
24,
982
],
[
982,
63,
1476
]
],
[
[
826,
1,
1131
],
[
1131,
24,
1476
]
],
[
[
826,
63,
1051
],
[
1051,
24,
1476
]
],
[
[
826,
24,
129
],
[
129,
25,
1476
]
],
[
[
826,
25,
384
],
[
384,
25,
1476
]
],
[
[
826,
63,
600
],
[
600,
25,
1476
]
],
[
[
826,
24,
283
],
[
283,
64,
1476
]
]
] | [
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Ergotamine",
"{u} (Compound) resembles {v} (Compound)",
"Ergometrine"
],
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Ergotamine",
"{u} (Compound) resembles {v} (Compound)",
"Methysergide"
],
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Ergotamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
]
] | Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Ergotamine (Compound) resembles Ergometrine (Compound) and Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Ergotamine (Compound) resembles Methysergide (Compound) and Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Brigatinib
Ergotamine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Brigatinib
Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Brigatinib
Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Brigatinib |
DB00421 | DB01069 | 443 | 401 | [
"DDInter1707",
"DDInter1533"
] | Spironolactone | Promethazine | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.[A11837, A178246] It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243, L6187] | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Moderate | 1 | [
[
[
443,
24,
401
]
],
[
[
443,
24,
1264
],
[
1264,
63,
401
]
],
[
[
443,
24,
104
],
[
104,
24,
401
]
],
[
[
443,
6,
4973
],
[
4973,
45,
401
]
],
[
[
443,
21,
28787
],
[
28787,
60,
401
]
],
[
[
443,
24,
286
],
[
286,
62,
401
]
],
[
[
443,
1,
312
],
[
312,
24,
401
]
],
[
[
443,
25,
1250
],
[
1250,
63,
401
]
],
[
[
443,
25,
543
],
[
543,
24,
401
]
],
[
[
443,
63,
475
],
[
475,
24,
401
]
]
] | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Spironolactone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Promethazine"
]
],
[
[
"Spironolactone",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Promethazine"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Promethazine"
]
],
[
[
"Spironolactone",
"{u} (Compound) resembles {v} (Compound)",
"Eplerenone"
],
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Spironolactone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Spironolactone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
]
] | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Spironolactone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Promethazine (Compound)
Spironolactone (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Promethazine (Compound)
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Promethazine
Spironolactone (Compound) resembles Eplerenone (Compound) and Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Spironolactone may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Spironolactone may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine |
DB00092 | DB00281 | 58 | 608 | [
"DDInter40",
"DDInter1066"
] | Alefacept | Lidocaine | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication . In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L5930, L5948, F4468]. Nevertheless, lidocaine's local anesthetic action sees its use in many medical situations or circumstances that may benefit from its action, including the treatment of premature ejaculation . Regardless, lidocaine is currently available as a relatively non-expensive generic medication that is written for in millions of prescriptions internationally on a yearly basis. It is even included in the World Health Organization's List of Essential Medicines . | Moderate | 1 | [
[
[
58,
24,
608
]
],
[
[
58,
24,
1101
],
[
1101,
62,
608
]
],
[
[
58,
25,
1510
],
[
1510,
62,
608
]
],
[
[
58,
24,
362
],
[
362,
23,
608
]
],
[
[
58,
24,
1093
],
[
1093,
63,
608
]
],
[
[
58,
63,
1057
],
[
1057,
24,
608
]
],
[
[
58,
24,
494
],
[
494,
24,
608
]
],
[
[
58,
25,
976
],
[
976,
63,
608
]
],
[
[
58,
24,
1401
],
[
1401,
74,
608
]
],
[
[
58,
24,
1101
],
[
1101,
6,
6017
],
[
6017,
45,
608
]
]
] | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
],
[
"Procainamide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Lidocaine"
]
]
] | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Alefacept may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Alefacept may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Procainamide and Procainamide (Compound) resembles Lidocaine (Compound) and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Lidocaine (Compound) |
DB00250 | DB05773 | 10 | 1,047 | [
"DDInter475",
"DDInter1848"
] | Dapsone | Trastuzumab emtansine | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity. | Moderate | 1 | [
[
[
10,
24,
1047
]
],
[
[
10,
24,
375
],
[
375,
63,
1047
]
],
[
[
10,
24,
1112
],
[
1112,
24,
1047
]
],
[
[
10,
63,
1057
],
[
1057,
24,
1047
]
],
[
[
10,
25,
1327
],
[
1327,
24,
1047
]
],
[
[
10,
24,
4
],
[
4,
25,
1047
]
],
[
[
10,
24,
1468
],
[
1468,
64,
1047
]
],
[
[
10,
24,
375
],
[
375,
24,
381
],
[
381,
63,
1047
]
],
[
[
10,
24,
381
],
[
381,
63,
375
],
[
375,
63,
1047
]
],
[
[
10,
24,
310
],
[
310,
63,
1091
],
[
1091,
24,
1047
]
]
] | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Auranofin"
],
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium aurothiomalate"
],
[
"Sodium aurothiomalate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium aurothiomalate"
],
[
"Sodium aurothiomalate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
]
] | Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Auranofin and Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Dapsone may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Trastuzumab emtansine
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Trastuzumab emtansine
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate and Sodium aurothiomalate may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate and Sodium aurothiomalate may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine |
DB00384 | DB08907 | 1,275 | 1,344 | [
"DDInter1859",
"DDInter280"
] | Triamterene | Canagliflozin | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it acts on the distal nephron where only a small fraction of sodium ion reabsorption occurs, triamterene is reported to have limited diuretic efficacy. Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia. Triamterene is a weak antagonist of folic acid, and a photosensitizing drug. Triamterene was approved by the Food and Drug Administration in the U.S. in 1964. Currently, triamterene is used in the treatment of edema associated with various | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients . | Moderate | 1 | [
[
[
1275,
24,
1344
]
],
[
[
1275,
24,
549
],
[
549,
1,
1344
]
],
[
[
1275,
21,
28962
],
[
28962,
60,
1344
]
],
[
[
1275,
24,
1486
],
[
1486,
24,
1344
]
],
[
[
1275,
24,
1019
],
[
1019,
63,
1344
]
],
[
[
1275,
63,
999
],
[
999,
24,
1344
]
],
[
[
1275,
24,
549
],
[
549,
6,
16207
],
[
16207,
45,
1344
]
],
[
[
1275,
21,
28962
],
[
28962,
60,
664
],
[
664,
24,
1344
]
],
[
[
1275,
21,
28681
],
[
28681,
60,
549
],
[
549,
1,
1344
]
],
[
[
1275,
24,
1486
],
[
1486,
24,
549
],
[
549,
1,
1344
]
]
] | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Triamterene",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperkalaemia"
],
[
"Hyperkalaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) binds {v} (Gene)",
"SLC5A1"
],
[
"SLC5A1",
"{u} (Gene) is bound by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Triamterene",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperkalaemia"
],
[
"Hyperkalaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Perindopril"
],
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Triamterene",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
]
] | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Triamterene (Compound) causes Hyperkalaemia (Side Effect) and Hyperkalaemia (Side Effect) is caused by Canagliflozin (Compound)
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) binds SLC5A1 (Gene) and SLC5A1 (Gene) is bound by Canagliflozin (Compound)
Triamterene (Compound) causes Hyperkalaemia (Side Effect) and Hyperkalaemia (Side Effect) is caused by Perindopril (Compound) and Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Triamterene (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Dapagliflozin (Compound) and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound) |
DB00641 | DB06414 | 467 | 655 | [
"DDInter1675",
"DDInter703"
] | Simvastatin | Etravirine | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral agents. On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. Etravarine must always be used in combination with other antiretroviral drugs. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1), and consequently blocks DNA-dependent and RNA-dependent polymerase activity. Etravirine does not inhibit human DNA polymerase alpha, beta or gamma. Common side effects of use include mild to moderate rash within the first 6 weeks of therapy, nausea, diarrhea and peripheral neuropathy. Patients are advised to immediately contact their healthcare provider if a rash develops. In 2009, postmarketing case reports of Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme, and other hypersensitivity reactions lead to a revision of etravirine's "Warnings and Precautions," as well as notification of health care providers. In 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development of rashes in patients taking etravirine, lead to a modification of etravirine's monograph. | Moderate | 1 | [
[
[
467,
24,
655
]
],
[
[
467,
6,
4973
],
[
4973,
45,
655
]
],
[
[
467,
21,
28680
],
[
28680,
60,
655
]
],
[
[
467,
63,
1101
],
[
1101,
23,
655
]
],
[
[
467,
63,
1057
],
[
1057,
24,
655
]
],
[
[
467,
24,
1488
],
[
1488,
24,
655
]
],
[
[
467,
24,
466
],
[
466,
63,
655
]
],
[
[
467,
25,
384
],
[
384,
63,
655
]
],
[
[
467,
25,
609
],
[
609,
24,
655
]
],
[
[
467,
23,
126
],
[
126,
24,
655
]
]
] | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Simvastatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Etravirine"
]
],
[
[
"Simvastatin",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Etravirine"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etravirine"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Simvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
]
] | Simvastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Simvastatin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Etravirine (Compound)
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Etravirine
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Simvastatin may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Simvastatin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Simvastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Etravirine |
DB06603 | DB12825 | 39 | 1,375 | [
"DDInter1387",
"DDInter1032"
] | Panobinostat | Lefamulin | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity. | Major | 2 | [
[
[
39,
25,
1375
]
],
[
[
39,
62,
112
],
[
112,
23,
1375
]
],
[
[
39,
24,
159
],
[
159,
63,
1375
]
],
[
[
39,
25,
976
],
[
976,
24,
1375
]
],
[
[
39,
63,
1101
],
[
1101,
24,
1375
]
],
[
[
39,
24,
659
],
[
659,
24,
1375
]
],
[
[
39,
64,
792
],
[
792,
24,
1375
]
],
[
[
39,
25,
676
],
[
676,
63,
1375
]
],
[
[
39,
64,
1069
],
[
1069,
25,
1375
]
],
[
[
39,
25,
877
],
[
877,
64,
1375
]
]
] | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Panobinostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lefamulin"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
]
] | Panobinostat may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Panobinostat may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Panobinostat may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Panobinostat may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Panobinostat may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Lefamulin
Panobinostat may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Lefamulin |
DB00741 | DB01067 | 167 | 959 | [
"DDInter885",
"DDInter826"
] | Hydrocortisone | Glipizide | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®. | Moderate | 1 | [
[
[
167,
24,
959
]
],
[
[
167,
63,
245
],
[
245,
40,
959
]
],
[
[
167,
24,
1411
],
[
1411,
1,
959
]
],
[
[
167,
6,
8374
],
[
8374,
45,
959
]
],
[
[
167,
21,
28698
],
[
28698,
60,
959
]
],
[
[
167,
24,
1551
],
[
1551,
23,
959
]
],
[
[
167,
1,
1220
],
[
1220,
63,
959
]
],
[
[
167,
24,
519
],
[
519,
63,
959
]
],
[
[
167,
23,
1674
],
[
1674,
24,
959
]
],
[
[
167,
24,
1338
],
[
1338,
24,
959
]
]
] | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Glipizide"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Glipizide"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyldopa"
],
[
"Methyldopa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glipizide"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
],
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
]
] | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
Hydrocortisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Glipizide (Compound)
Hydrocortisone (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Glipizide (Compound)
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa and Methyldopa may cause a minor interaction that can limit clinical effects when taken with Glipizide
Hydrocortisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Glipizide |
DB01166 | DB01764 | 477 | 805 | [
"DDInter379",
"DDInter469"
] | Cilostazol | Dalfopristin | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. | Major | 2 | [
[
[
477,
25,
805
]
],
[
[
477,
6,
8374
],
[
8374,
45,
805
]
],
[
[
477,
63,
222
],
[
222,
23,
805
]
],
[
[
477,
25,
283
],
[
283,
62,
805
]
],
[
[
477,
25,
1618
],
[
1618,
63,
805
]
],
[
[
477,
25,
609
],
[
609,
24,
805
]
],
[
[
477,
24,
478
],
[
478,
63,
805
]
],
[
[
477,
64,
11
],
[
11,
24,
805
]
],
[
[
477,
63,
1133
],
[
1133,
24,
805
]
],
[
[
477,
24,
392
],
[
392,
24,
805
]
]
] | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalfopristin"
]
],
[
[
"Cilostazol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dalfopristin"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dalfopristin"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dalfopristin"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
]
] | Cilostazol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Dalfopristin
Cilostazol may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Dalfopristin
Cilostazol may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Cilostazol may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Cilostazol may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin |
DB11581 | DB15762 | 1,456 | 725 | [
"DDInter1926",
"DDInter1644"
] | Venetoclax | Satralizumab | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries. Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax. Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells. A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central nervous system (CNS) involving demyelinating lesions in the optic nerve, spinal cord, brainstem, and cerebrum. Some of the pro-inflammatory mechanisms involved in NMOSD are thought to be mediated, at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased permeability of the blood-brain barrier, which allows for the passage of pro-inflammatory mediators into the CNS.[A218546,A218551] Satralizumab is thought to exert its therapeutic benefits by blocking IL-6 receptors and, subsequently, these inflammatory responses. Enspryng®, a satralizumab formulation developed by Chugai Pharmaceutical and Roche, is uniquely formulated with "recycling antibody technology" whereby the association of satralizumab to IL-6 receptors occurs in a pH-dependent manner - this allows satralizumab to bind an IL-6 receptor until it reaches an endosome, after which the drug may dissociate from the receptor and move back into the plasma to act again. This novel mechanism effectively increases the duration of action of satralizumab, as it allows for single drug molecules to interact with multiple endogenous IL-6 receptors prior to elimination. Satralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive patients with NMOSD. It received subsequent approvals in Switzerland and Japan, and was approved for use by the FDA in August 2020, becoming the 3rd treatment to receive FDA approval for NMOSD (after [eculizumab] in June 2019 and [inebilizumab] in June 2020). | Moderate | 1 | [
[
[
1456,
24,
725
]
],
[
[
1456,
63,
1362
],
[
1362,
24,
725
]
],
[
[
1456,
64,
384
],
[
384,
24,
725
]
],
[
[
1456,
24,
738
],
[
738,
24,
725
]
],
[
[
1456,
64,
1066
],
[
1066,
25,
725
]
],
[
[
1456,
63,
1531
],
[
1531,
25,
725
]
],
[
[
1456,
25,
676
],
[
676,
25,
725
]
],
[
[
1456,
63,
1362
],
[
1362,
64,
384
],
[
384,
24,
725
]
],
[
[
1456,
64,
384
],
[
384,
25,
1362
],
[
1362,
24,
725
]
],
[
[
1456,
63,
713
],
[
713,
24,
1362
],
[
1362,
24,
725
]
]
] | [
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
]
] | Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Venetoclax may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Venetoclax may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Satralizumab
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may lead to a major life threatening interaction when taken with Satralizumab
Venetoclax may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Satralizumab
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Venetoclax may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab |
DB01039 | DB08870 | 535 | 850 | [
"DDInter718",
"DDInter228"
] | Fenofibrate | Brentuximab vedotin | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission. The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care. Importantly, bleomycin - a highly toxic agent - was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease. | Moderate | 1 | [
[
[
535,
24,
850
]
],
[
[
535,
63,
267
],
[
267,
24,
850
]
],
[
[
535,
24,
959
],
[
959,
24,
850
]
],
[
[
535,
64,
467
],
[
467,
24,
850
]
],
[
[
535,
25,
14
],
[
14,
24,
850
]
],
[
[
535,
24,
384
],
[
384,
63,
850
]
],
[
[
535,
40,
831
],
[
831,
24,
850
]
],
[
[
535,
25,
1510
],
[
1510,
64,
850
]
],
[
[
535,
25,
1377
],
[
1377,
25,
850
]
],
[
[
535,
63,
267
],
[
267,
24,
788
],
[
788,
24,
850
]
]
] | [
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Fenofibrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Fenofibrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Fenofibrate",
"{u} (Compound) resembles {v} (Compound)",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Fenofibrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Fenofibrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Fenofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
]
] | Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fenofibrate may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fenofibrate may lead to a major life threatening interaction when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fenofibrate (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fenofibrate may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin
Fenofibrate may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin
Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin |
DB00927 | DB01601 | 1,559 | 833 | [
"DDInter712",
"DDInter1089"
] | Famotidine | Lopinavir | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings. | Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and extensive biotransformation. Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity. Like many other protease inhibitors (e.g. [saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself cannot be cleaved, thus preventing the activity of the HIV-1 protease. Lopinavir was previously under investigation in combination with ritonavir for the treatment of COVID-19 caused by SARS-CoV-2. | Moderate | 1 | [
[
[
1559,
24,
833
]
],
[
[
1559,
24,
1327
],
[
1327,
40,
833
]
],
[
[
1559,
25,
915
],
[
915,
40,
833
]
],
[
[
1559,
6,
10215
],
[
10215,
45,
833
]
],
[
[
1559,
24,
144
],
[
144,
63,
833
]
],
[
[
1559,
63,
1555
],
[
1555,
24,
833
]
],
[
[
1559,
24,
480
],
[
480,
24,
833
]
],
[
[
1559,
23,
286
],
[
286,
63,
833
]
],
[
[
1559,
24,
1011
],
[
1011,
64,
833
]
],
[
[
1559,
24,
57
],
[
57,
25,
833
]
]
] | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lopinavir"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} (Compound) resembles {v} (Compound)",
"Lopinavir"
]
],
[
[
"Famotidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} (Compound) resembles {v} (Compound)",
"Lopinavir"
]
],
[
[
"Famotidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Lopinavir"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lopinavir"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lopinavir"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lopinavir"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lopinavir"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lopinavir"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lopinavir"
]
]
] | Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) resembles Lopinavir (Compound)
Famotidine may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir (Compound) resembles Lopinavir (Compound)
Famotidine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Lopinavir (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir
Famotidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Lopinavir
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Lopinavir |
DB01319 | DB08916 | 34 | 26 | [
"DDInter777",
"DDInter32"
] | Fosamprenavir | Afatinib | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test . Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim . | Moderate | 1 | [
[
[
34,
24,
26
]
],
[
[
34,
63,
883
],
[
883,
40,
26
]
],
[
[
34,
21,
28809
],
[
28809,
60,
26
]
],
[
[
34,
24,
124
],
[
124,
63,
26
]
],
[
[
34,
23,
466
],
[
466,
63,
26
]
],
[
[
34,
24,
129
],
[
129,
24,
26
]
],
[
[
34,
62,
609
],
[
609,
24,
26
]
],
[
[
34,
63,
1220
],
[
1220,
24,
26
]
],
[
[
34,
1,
1091
],
[
1091,
24,
26
]
],
[
[
34,
23,
1374
],
[
1374,
24,
26
]
]
] | [
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Afatinib"
]
],
[
[
"Fosamprenavir",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Afatinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Fosamprenavir",
"{u} (Compound) resembles {v} (Compound)",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
]
] | Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Afatinib (Compound)
Fosamprenavir (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Afatinib (Compound)
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Afatinib
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Afatinib
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Afatinib
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Afatinib
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Afatinib
Fosamprenavir (Compound) resembles Amprenavir (Compound) and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Afatinib
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Afatinib |
DB12301 | DB12941 | 907 | 466 | [
"DDInter585",
"DDInter481"
] | Doravirine | Darolutamide | Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg). Doravirine is formally indicated for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment experience, further expanding the possibility and choice of therapeutic treatments available for the management of HIV-1 infection. | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019. | Moderate | 1 | [
[
[
907,
24,
466
]
],
[
[
907,
62,
1374
],
[
1374,
23,
466
]
],
[
[
907,
23,
283
],
[
283,
23,
466
]
],
[
[
907,
23,
159
],
[
159,
62,
466
]
],
[
[
907,
64,
1040
],
[
1040,
24,
466
]
],
[
[
907,
62,
392
],
[
392,
24,
466
]
],
[
[
907,
63,
98
],
[
98,
24,
466
]
],
[
[
907,
23,
1619
],
[
1619,
24,
466
]
],
[
[
907,
24,
982
],
[
982,
63,
466
]
],
[
[
907,
64,
1220
],
[
1220,
25,
466
]
]
] | [
[
[
"Doravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Doravirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Doravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Doravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Doravirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
]
]
] | Doravirine may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Doravirine may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Doravirine may lead to a major life threatening interaction when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Doravirine may cause a minor interaction that can limit clinical effects when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Doravirine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Doravirine may cause a minor interaction that can limit clinical effects when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Doravirine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Doravirine may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Darolutamide |
DB01390 | DB01576 | 1,117 | 93 | [
"DDInter1683",
"DDInter526"
] | Sodium bicarbonate | Dextroamphetamine | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Dextroamphetamine is the dextrorotatory enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label]. | Moderate | 1 | [
[
[
1117,
24,
93
]
],
[
[
1117,
63,
80
],
[
80,
40,
93
]
],
[
[
1117,
24,
1529
],
[
1529,
40,
93
]
],
[
[
1117,
63,
22
],
[
22,
24,
93
]
],
[
[
1117,
21,
28898
],
[
28898,
60,
93
]
],
[
[
1117,
63,
1445
],
[
1445,
35,
93
]
],
[
[
1117,
63,
80
],
[
80,
40,
11447
],
[
11447,
1,
93
]
],
[
[
1117,
24,
1529
],
[
1529,
40,
11447
],
[
11447,
1,
93
]
],
[
[
1117,
63,
22
],
[
22,
74,
73
],
[
73,
1,
93
]
],
[
[
1117,
21,
28898
],
[
28898,
60,
73
],
[
73,
1,
93
]
]
] | [
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextroamphetamine"
]
],
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
[
"Amphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Dextroamphetamine"
]
],
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Dextroamphetamine"
]
],
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextroamphetamine"
]
],
[
[
"Sodium bicarbonate",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dextroamphetamine"
]
],
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextroamphetamine"
]
],
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
[
"Amphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Fenproporex"
],
[
"Fenproporex",
"{u} (Compound) resembles {v} (Compound)",
"Dextroamphetamine"
]
],
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Fenproporex"
],
[
"Fenproporex",
"{u} (Compound) resembles {v} (Compound)",
"Dextroamphetamine"
]
],
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound)",
"Dextroamphetamine"
]
],
[
[
"Sodium bicarbonate",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Phentermine"
],
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound)",
"Dextroamphetamine"
]
]
] | Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Dextroamphetamine (Compound)
Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Dextroamphetamine (Compound)
Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Dextroamphetamine
Sodium bicarbonate (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Dextroamphetamine (Compound)
Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Dextroamphetamine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Dextroamphetamine
Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Fenproporex (Compound) and Fenproporex (Compound) resembles Dextroamphetamine (Compound)
Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Fenproporex (Compound) and Fenproporex (Compound) resembles Dextroamphetamine (Compound)
Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) resembles Phentermine (Compound) and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) resembles Dextroamphetamine (Compound)
Sodium bicarbonate (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Phentermine (Compound) and Phentermine (Compound) resembles Dextroamphetamine (Compound) |
DB00991 | DB04932 | 97 | 1,564 | [
"DDInter1358",
"DDInter491"
] | Oxaprozin | Defibrotide | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries. In the USA it is was approved in March, 2016 as Defitelio. | Moderate | 1 | [
[
[
97,
24,
1564
]
],
[
[
97,
24,
1039
],
[
1039,
24,
1564
]
],
[
[
97,
24,
738
],
[
738,
63,
1564
]
],
[
[
97,
63,
121
],
[
121,
24,
1564
]
],
[
[
97,
40,
998
],
[
998,
24,
1564
]
],
[
[
97,
63,
1347
],
[
1347,
25,
1564
]
],
[
[
97,
25,
330
],
[
330,
64,
1564
]
],
[
[
97,
64,
1172
],
[
1172,
25,
1564
]
],
[
[
97,
24,
936
],
[
936,
64,
1564
]
],
[
[
97,
25,
500
],
[
500,
25,
1564
]
]
] | [
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Oxaprozin",
"{u} (Compound) resembles {v} (Compound)",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Oxaprozin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
],
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Oxaprozin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
],
[
"Cangrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Oxaprozin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
]
] | Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Oxaprozin (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Defibrotide
Oxaprozin may lead to a major life threatening interaction when taken with Ramucirumab and Ramucirumab may lead to a major life threatening interaction when taken with Defibrotide
Oxaprozin may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Defibrotide
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor and Cangrelor may lead to a major life threatening interaction when taken with Defibrotide
Oxaprozin may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Defibrotide |
DB00734 | DB00738 | 1,664 | 485 | [
"DDInter1605",
"DDInter1420"
] | Risperidone | Pentamidine | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone). Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
1664,
24,
485
]
],
[
[
1664,
6,
12523
],
[
12523,
45,
485
]
],
[
[
1664,
18,
5833
],
[
5833,
57,
485
]
],
[
[
1664,
21,
29097
],
[
29097,
60,
485
]
],
[
[
1664,
23,
112
],
[
112,
62,
485
]
],
[
[
1664,
24,
971
],
[
971,
63,
485
]
],
[
[
1664,
63,
322
],
[
322,
24,
485
]
],
[
[
1664,
1,
519
],
[
519,
63,
485
]
],
[
[
1664,
25,
877
],
[
877,
64,
485
]
],
[
[
1664,
64,
11
],
[
11,
25,
485
]
]
] | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Risperidone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Pentamidine"
]
],
[
[
"Risperidone",
"{u} (Compound) downregulates {v} (Gene)",
"ACAT2"
],
[
"ACAT2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Pentamidine"
]
],
[
[
"Risperidone",
"{u} (Compound) causes {v} (Side Effect)",
"Eye pain"
],
[
"Eye pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pentamidine"
]
],
[
[
"Risperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pentamidine"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Risperidone",
"{u} (Compound) resembles {v} (Compound)",
"Paliperidone"
],
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Risperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
]
],
[
[
"Risperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
]
]
] | Risperidone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pentamidine (Compound)
Risperidone (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is downregulated by Pentamidine (Compound)
Risperidone (Compound) causes Eye pain (Side Effect) and Eye pain (Side Effect) is caused by Pentamidine (Compound)
Risperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pentamidine
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Risperidone (Compound) resembles Paliperidone (Compound) and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Risperidone may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Pentamidine
Risperidone may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Pentamidine |
DB01416 | DB09268 | 1,024 | 1,662 | [
"DDInter326",
"DDInter1464"
] | Cefpodoxime | Picosulfuric acid | Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years. | Moderate | 1 | [
[
[
1024,
24,
1662
]
],
[
[
1024,
63,
597
],
[
597,
24,
1662
]
],
[
[
1024,
40,
1558
],
[
1558,
24,
1662
]
],
[
[
1024,
1,
149
],
[
149,
24,
1662
]
],
[
[
1024,
63,
597
],
[
597,
25,
484
],
[
484,
63,
1662
]
],
[
[
1024,
40,
1558
],
[
1558,
63,
597
],
[
597,
24,
1662
]
],
[
[
1024,
63,
361
],
[
361,
62,
1252
],
[
1252,
23,
1662
]
],
[
[
1024,
1,
149
],
[
149,
24,
597
],
[
597,
24,
1662
]
],
[
[
1024,
1,
1087
],
[
1087,
63,
597
],
[
597,
24,
1662
]
],
[
[
1024,
63,
1448
],
[
1448,
63,
1027
],
[
1027,
24,
1662
]
]
] | [
[
[
"Cefpodoxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cefpodoxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cefpodoxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefoxitin"
],
[
"Cefoxitin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cefpodoxime",
"{u} (Compound) resembles {v} (Compound)",
"Ceftazidime"
],
[
"Ceftazidime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cefpodoxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cefpodoxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefoxitin"
],
[
"Cefoxitin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cefpodoxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cefpodoxime",
"{u} (Compound) resembles {v} (Compound)",
"Ceftazidime"
],
[
"Ceftazidime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cefpodoxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefotaxime"
],
[
"Cefotaxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Cefpodoxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
],
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
]
] | Cefpodoxime may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cefpodoxime (Compound) resembles Cefoxitin (Compound) and Cefoxitin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cefpodoxime (Compound) resembles Ceftazidime (Compound) and Ceftazidime may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cefpodoxime may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cefpodoxime (Compound) resembles Cefoxitin (Compound) and Cefoxitin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cefpodoxime may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Cefpodoxime (Compound) resembles Ceftazidime (Compound) and Ceftazidime may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cefpodoxime (Compound) resembles Cefotaxime (Compound) and Cefotaxime may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Cefpodoxime may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid |
DB01206 | DB08868 | 37 | 1,011 | [
"DDInter1086",
"DDInter737"
] | Lomustine | Fingolimod | An alkylating agent of value against both hematologic malignancies and solid tumors. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Major | 2 | [
[
[
37,
25,
1011
]
],
[
[
37,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
37,
21,
28852
],
[
28852,
60,
1011
]
],
[
[
37,
24,
242
],
[
242,
63,
1011
]
],
[
[
37,
24,
1136
],
[
1136,
24,
1011
]
],
[
[
37,
64,
752
],
[
752,
24,
1011
]
],
[
[
37,
63,
267
],
[
267,
24,
1011
]
],
[
[
37,
25,
976
],
[
976,
64,
1011
]
],
[
[
37,
64,
1066
],
[
1066,
25,
1011
]
],
[
[
37,
63,
611
],
[
611,
25,
1011
]
]
] | [
[
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Lomustine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fingolimod"
]
],
[
[
"Lomustine",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fingolimod"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
],
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
],
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
]
] | Lomustine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Lomustine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Fingolimod (Compound)
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Lomustine may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Lomustine may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Fingolimod
Lomustine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Fingolimod
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine and Dacarbazine may lead to a major life threatening interaction when taken with Fingolimod |
DB00531 | DB15066 | 450 | 445 | [
"DDInter456",
"DDInter821"
] | Cyclophosphamide | Givosiran | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and gastrotoxicity. Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies involved non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and liver transplantation in refractory cases. Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of genetic disorders. | Moderate | 1 | [
[
[
450,
24,
445
]
],
[
[
450,
63,
1555
],
[
1555,
24,
445
]
],
[
[
450,
24,
1287
],
[
1287,
24,
445
]
],
[
[
450,
35,
1532
],
[
1532,
24,
445
]
],
[
[
450,
25,
1377
],
[
1377,
25,
445
]
],
[
[
450,
24,
629
],
[
629,
25,
445
]
],
[
[
450,
63,
1555
],
[
1555,
24,
850
],
[
850,
24,
445
]
],
[
[
450,
24,
1287
],
[
1287,
63,
1555
],
[
1555,
24,
445
]
],
[
[
450,
35,
1532
],
[
1532,
63,
1555
],
[
1555,
24,
445
]
],
[
[
450,
24,
126
],
[
126,
24,
1039
],
[
1039,
24,
445
]
]
] | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Cyclophosphamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Givosiran"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Givosiran"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
]
] | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Cyclophosphamide (Compound) resembles Ifosfamide (Compound) and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Cyclophosphamide may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Givosiran
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Givosiran
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Cyclophosphamide (Compound) resembles Ifosfamide (Compound) and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran |
DB00373 | DB06691 | 461 | 849 | [
"DDInter1809",
"DDInter1155"
] | Timolol | Mepyramine | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
461,
24,
849
]
],
[
[
461,
6,
12523
],
[
12523,
45,
849
]
],
[
[
461,
24,
770
],
[
770,
24,
849
]
],
[
[
461,
63,
1648
],
[
1648,
24,
849
]
],
[
[
461,
24,
407
],
[
407,
63,
849
]
],
[
[
461,
1,
729
],
[
729,
24,
849
]
],
[
[
461,
6,
12523
],
[
12523,
45,
23
],
[
23,
40,
849
]
],
[
[
461,
24,
770
],
[
770,
63,
1594
],
[
1594,
24,
849
]
],
[
[
461,
63,
1648
],
[
1648,
24,
1594
],
[
1594,
24,
849
]
],
[
[
461,
24,
1376
],
[
1376,
40,
11244
],
[
11244,
1,
849
]
]
] | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Timolol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Mepyramine"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Timolol",
"{u} (Compound) resembles {v} (Compound)",
"Penbutolol"
],
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Timolol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Rosiglitazone"
],
[
"Rosiglitazone",
"{u} (Compound) resembles {v} (Compound)",
"Mepyramine"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound)",
"Pheniramine"
],
[
"Pheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Mepyramine"
]
]
] | Timolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Timolol (Compound) resembles Penbutolol (Compound) and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Timolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Rosiglitazone (Compound) and Rosiglitazone (Compound) resembles Mepyramine (Compound)
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Mepyramine (Compound) |
DB00563 | DB05239 | 663 | 866 | [
"DDInter1174",
"DDInter425"
] | Methotrexate | Cobimetinib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. | Moderate | 1 | [
[
[
663,
24,
866
]
],
[
[
663,
24,
214
],
[
214,
63,
866
]
],
[
[
663,
24,
984
],
[
984,
24,
866
]
],
[
[
663,
63,
482
],
[
482,
24,
866
]
],
[
[
663,
25,
998
],
[
998,
24,
866
]
],
[
[
663,
25,
334
],
[
334,
64,
866
]
],
[
[
663,
24,
1419
],
[
1419,
25,
866
]
],
[
[
663,
64,
1066
],
[
1066,
25,
866
]
],
[
[
663,
24,
800
],
[
800,
64,
866
]
],
[
[
663,
63,
152
],
[
152,
25,
866
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
],
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
],
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
],
[
"Duvelisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosentan"
],
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
]
] | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Danazol and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Methotrexate may lead to a major life threatening interaction when taken with Phenylbutazone and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Methotrexate may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen and Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Cobimetinib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Cobimetinib
Methotrexate may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Cobimetinib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib may lead to a major life threatening interaction when taken with Cobimetinib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bosentan and Bosentan may lead to a major life threatening interaction when taken with Cobimetinib |
DB00270 | DB00372 | 1,428 | 999 | [
"DDInter993",
"DDInter1793"
] | Isradipine | Thiethylperazine | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension. | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Moderate | 1 | [
[
[
1428,
24,
999
]
],
[
[
1428,
1,
1081
],
[
1081,
63,
999
]
],
[
[
1428,
24,
1614
],
[
1614,
63,
999
]
],
[
[
1428,
40,
854
],
[
854,
63,
999
]
],
[
[
1428,
24,
475
],
[
475,
24,
999
]
],
[
[
1428,
63,
1648
],
[
1648,
24,
999
]
],
[
[
1428,
24,
593
],
[
593,
64,
999
]
],
[
[
1428,
1,
1081
],
[
1081,
63,
1614
],
[
1614,
63,
999
]
],
[
[
1428,
24,
1614
],
[
1614,
24,
17
],
[
17,
63,
999
]
],
[
[
1428,
24,
433
],
[
433,
63,
417
],
[
417,
23,
999
]
]
] | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Isradipine",
"{u} (Compound) resembles {v} (Compound)",
"Nicardipine"
],
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Isradipine",
"{u} (Compound) resembles {v} (Compound)",
"Nimodipine"
],
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Isradipine",
"{u} (Compound) resembles {v} (Compound)",
"Nicardipine"
],
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Thiethylperazine"
]
]
] | Isradipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Isradipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Thiethylperazine
Isradipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thiethylperazine |
DB00877 | DB08816 | 629 | 578 | [
"DDInter1678",
"DDInter1802"
] | Sirolimus | Ticagrelor | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Moderate | 1 | [
[
[
629,
24,
578
]
],
[
[
629,
6,
4973
],
[
4973,
45,
578
]
],
[
[
629,
21,
28646
],
[
28646,
60,
578
]
],
[
[
629,
24,
336
],
[
336,
23,
578
]
],
[
[
629,
24,
1586
],
[
1586,
62,
578
]
],
[
[
629,
63,
1428
],
[
1428,
23,
578
]
],
[
[
629,
23,
907
],
[
907,
62,
578
]
],
[
[
629,
25,
1011
],
[
1011,
62,
578
]
],
[
[
629,
63,
723
],
[
723,
24,
578
]
],
[
[
629,
24,
868
],
[
868,
63,
578
]
]
] | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Sirolimus",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Ticagrelor"
]
],
[
[
"Sirolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
"Unspecified disorder of skin and subcutaneous tissue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ticagrelor"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
],
[
"Levamlodipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Sirolimus",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
]
] | Sirolimus (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Sirolimus (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine and Levamlodipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Sirolimus may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Sirolimus may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor |
DB01124 | DB05541 | 1,411 | 801 | [
"DDInter1828",
"DDInter239"
] | Tolbutamide | Brivaracetam | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to | Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 . | Minor | 0 | [
[
[
1411,
23,
801
]
],
[
[
1411,
62,
660
],
[
660,
23,
801
]
],
[
[
1411,
63,
303
],
[
303,
23,
801
]
],
[
[
1411,
64,
600
],
[
600,
23,
801
]
],
[
[
1411,
63,
999
],
[
999,
24,
801
]
],
[
[
1411,
24,
1264
],
[
1264,
24,
801
]
],
[
[
1411,
62,
1347
],
[
1347,
24,
801
]
],
[
[
1411,
62,
660
],
[
660,
24,
477
],
[
477,
23,
801
]
],
[
[
1411,
63,
303
],
[
303,
63,
600
],
[
600,
23,
801
]
],
[
[
1411,
63,
168
],
[
168,
24,
477
],
[
477,
23,
801
]
]
] | [
[
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Tolbutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brivaracetam"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brivaracetam"
]
],
[
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brivaracetam"
]
],
[
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
]
] | Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Tolbutamide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam
Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam
Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam |
DB00959 | DB09020 | 1,486 | 28 | [
"DDInter1191",
"DDInter212"
] | Methylprednisolone | Bisacodyl | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956 but has been used as a laxative since 1952. | Moderate | 1 | [
[
[
1486,
24,
28
]
],
[
[
1486,
18,
20113
],
[
20113,
46,
28
]
],
[
[
1486,
7,
3603
],
[
3603,
46,
28
]
],
[
[
1486,
6,
1899
],
[
1899,
46,
28
]
],
[
[
1486,
7,
7669
],
[
7669,
57,
28
]
],
[
[
1486,
21,
28666
],
[
28666,
60,
28
]
],
[
[
1486,
25,
739
],
[
739,
24,
28
]
],
[
[
1486,
24,
938
],
[
938,
63,
28
]
],
[
[
1486,
40,
870
],
[
870,
24,
28
]
],
[
[
1486,
63,
954
],
[
954,
24,
28
]
]
] | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) downregulates {v} (Gene)",
"IER3"
],
[
"IER3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) upregulates {v} (Gene)",
"ZFP36"
],
[
"ZFP36",
"{u} (Gene) is upregulated by {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) binds {v} (Gene)",
"NR3C1"
],
[
"NR3C1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) upregulates {v} (Gene)",
"DDIT4"
],
[
"DDIT4",
"{u} (Gene) is downregulated by {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
],
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
]
] | Methylprednisolone (Compound) downregulates IER3 (Gene) and IER3 (Gene) is upregulated by Bisacodyl (Compound)
Methylprednisolone (Compound) upregulates ZFP36 (Gene) and ZFP36 (Gene) is upregulated by Bisacodyl (Compound)
Methylprednisolone (Compound) binds NR3C1 (Gene) and NR3C1 (Gene) is upregulated by Bisacodyl (Compound)
Methylprednisolone (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is downregulated by Bisacodyl (Compound)
Methylprednisolone (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Bisacodyl (Compound)
Methylprednisolone may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Methylprednisolone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl |
DB00400 | DB00945 | 353 | 1,479 | [
"DDInter843",
"DDInter20"
] | Griseofulvin | Acetylsalicylic acid | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) [FDA label]. Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a _non-selective cyclooxygenase (COX) inhibitor_ [A32682, A177268] and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others . Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants [FDA label]. | Minor | 0 | [
[
[
353,
23,
1479
]
],
[
[
353,
21,
29232
],
[
29232,
60,
1479
]
],
[
[
353,
24,
479
],
[
479,
23,
1479
]
],
[
[
353,
24,
877
],
[
877,
63,
1479
]
],
[
[
353,
24,
612
],
[
612,
24,
1479
]
],
[
[
353,
24,
279
],
[
279,
64,
1479
]
],
[
[
353,
24,
126
],
[
126,
25,
1479
]
],
[
[
353,
21,
29232
],
[
29232,
60,
11404
],
[
11404,
40,
1479
]
],
[
[
353,
24,
479
],
[
479,
7,
2900
],
[
2900,
45,
1479
]
],
[
[
353,
24,
877
],
[
877,
63,
1338
],
[
1338,
24,
1479
]
]
] | [
[
[
"Griseofulvin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Griseofulvin",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Acetylsalicylic acid"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verteporfin"
],
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
],
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Griseofulvin",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Salicylic acid"
],
[
"Salicylic acid",
"{u} (Compound) resembles {v} (Compound)",
"Acetylsalicylic acid"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} (Compound) upregulates {v} (Gene)",
"NFKBIA"
],
[
"NFKBIA",
"{u} (Gene) is bound by {v} (Compound)",
"Acetylsalicylic acid"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
],
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
]
] | Griseofulvin (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Acetylsalicylic acid (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Verteporfin and Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may lead to a major life threatening interaction when taken with Acetylsalicylic acid
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Acetylsalicylic acid
Griseofulvin (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Salicylic acid (Compound) and Salicylic acid (Compound) resembles Acetylsalicylic acid (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is bound by Acetylsalicylic acid (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid |
DB00010 | DB13074 | 1,649 | 877 | [
"DDInter1661",
"DDInter1110"
] | Sermorelin | Macimorelin | Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. | Moderate | 1 | [
[
[
1649,
24,
877
]
],
[
[
1649,
24,
176
],
[
176,
24,
877
]
],
[
[
1649,
24,
176
],
[
176,
24,
1247
],
[
1247,
23,
877
]
],
[
[
1649,
24,
1296
],
[
1296,
63,
1247
],
[
1247,
23,
877
]
],
[
[
1649,
24,
549
],
[
549,
62,
463
],
[
463,
24,
877
]
],
[
[
1649,
24,
176
],
[
176,
24,
1020
],
[
1020,
24,
877
]
],
[
[
1649,
24,
1296
],
[
1296,
63,
1020
],
[
1020,
24,
877
]
],
[
[
1649,
24,
245
],
[
245,
23,
1051
],
[
1051,
24,
877
]
],
[
[
1649,
24,
1002
],
[
1002,
63,
401
],
[
401,
25,
877
]
],
[
[
1649,
24,
176
],
[
176,
24,
388
],
[
388,
63,
877
]
]
] | [
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Macimorelin"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Macimorelin"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
],
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
],
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mecasermin rinfabate"
],
[
"Mecasermin rinfabate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
]
] | Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a minor interaction that can limit clinical effects when taken with Rifampicin and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Macimorelin
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin rinfabate and Mecasermin rinfabate may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin |
DB00682 | DB01415 | 126 | 1,521 | [
"DDInter1951",
"DDInter331"
] | Warfarin | Ceftibuten | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis. | Moderate | 1 | [
[
[
126,
24,
1521
]
],
[
[
126,
24,
665
],
[
665,
40,
1521
]
],
[
[
126,
63,
1145
],
[
1145,
1,
1521
]
],
[
[
126,
63,
149
],
[
149,
40,
1521
]
],
[
[
126,
63,
597
],
[
597,
24,
1521
]
],
[
[
126,
24,
665
],
[
665,
40,
1145
],
[
1145,
1,
1521
]
],
[
[
126,
63,
1145
],
[
1145,
1,
665
],
[
665,
40,
1521
]
],
[
[
126,
63,
149
],
[
149,
40,
665
],
[
665,
40,
1521
]
],
[
[
126,
24,
1453
],
[
1453,
1,
665
],
[
665,
40,
1521
]
],
[
[
126,
63,
597
],
[
597,
24,
665
],
[
665,
40,
1521
]
]
] | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftibuten"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Ceftibuten"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefdinir"
],
[
"Cefdinir",
"{u} (Compound) resembles {v} (Compound)",
"Ceftibuten"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftazidime"
],
[
"Ceftazidime",
"{u} (Compound) resembles {v} (Compound)",
"Ceftibuten"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftibuten"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefdinir"
],
[
"Cefdinir",
"{u} (Compound) resembles {v} (Compound)",
"Ceftibuten"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefdinir"
],
[
"Cefdinir",
"{u} (Compound) resembles {v} (Compound)",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Ceftibuten"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftazidime"
],
[
"Ceftazidime",
"{u} (Compound) resembles {v} (Compound)",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Ceftibuten"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftriaxone"
],
[
"Ceftriaxone",
"{u} (Compound) resembles {v} (Compound)",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Ceftibuten"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Ceftibuten"
]
]
] | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Ceftibuten (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefdinir and Cefdinir (Compound) resembles Ceftibuten (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ceftazidime and Ceftazidime (Compound) resembles Ceftibuten (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ceftibuten
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefdinir (Compound) and Cefdinir (Compound) resembles Ceftibuten (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefdinir and Cefdinir (Compound) resembles Cefuroxime (Compound) and Cefuroxime (Compound) resembles Ceftibuten (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ceftazidime and Ceftazidime (Compound) resembles Cefuroxime (Compound) and Cefuroxime (Compound) resembles Ceftibuten (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ceftriaxone and Ceftriaxone (Compound) resembles Cefuroxime (Compound) and Cefuroxime (Compound) resembles Ceftibuten (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Ceftibuten (Compound) |
DB00687 | DB00790 | 870 | 664 | [
"DDInter747",
"DDInter1431"
] | Fludrocortisone | Perindopril | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease. | Moderate | 1 | [
[
[
870,
24,
664
]
],
[
[
870,
63,
1638
],
[
1638,
1,
664
]
],
[
[
870,
24,
954
],
[
954,
40,
664
]
],
[
[
870,
24,
1058
],
[
1058,
1,
664
]
],
[
[
870,
21,
29291
],
[
29291,
60,
664
]
],
[
[
870,
23,
1117
],
[
1117,
62,
664
]
],
[
[
870,
24,
286
],
[
286,
62,
664
]
],
[
[
870,
24,
1296
],
[
1296,
63,
664
]
],
[
[
870,
63,
1179
],
[
1179,
24,
664
]
],
[
[
870,
1,
891
],
[
891,
63,
664
]
]
] | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perindopril"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
[
"Trandolapril",
"{u} (Compound) resembles {v} (Compound)",
"Perindopril"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} (Compound) resembles {v} (Compound)",
"Perindopril"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moexipril"
],
[
"Moexipril",
"{u} (Compound) resembles {v} (Compound)",
"Perindopril"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Muscular weakness"
],
[
"Muscular weakness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Perindopril"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
],
[
"Sodium bicarbonate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Perindopril"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Perindopril"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perindopril"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perindopril"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perindopril"
]
]
] | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Perindopril (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Perindopril (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Moexipril and Moexipril (Compound) resembles Perindopril (Compound)
Fludrocortisone (Compound) causes Muscular weakness (Side Effect) and Muscular weakness (Side Effect) is caused by Perindopril (Compound)
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate and Sodium bicarbonate may cause a minor interaction that can limit clinical effects when taken with Perindopril
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Perindopril
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Perindopril
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Perindopril
Fludrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Perindopril |
DB00526 | DB11627 | 1,555 | 1,367 | [
"DDInter1355",
"DDInter860"
] | Oxaliplatin | Hepatitis B Vaccine (Recombinant) | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, non-B hepatitis viruses. Hepatitis D virus, a defective virus requiring the “keeper function” of the hepatitis B virus, occurs either as a co-infection or super-infection in a HBsAg carrier. Transmission of the virus occurs through percutaneous contact with contaminated blood, serum or plasma. Infection may also occur by the exposure of mucous surfaces, or intact or damaged skin to other body fluids such as saliva, mucosal secretions and semen. There is no specific treatment for hepatitis. The incubation period may be as long as 6 months, followed by a very complex clinical course of an acute or chronic nature, often leading to hospitalization. Viral hepatitis caused by hepatitis B virus is a major worldwide health problem, though the incidence and epidemiology vary widely among geographical areas and population subgroups. In Canada, the United States and Northern Europe, 4% to 6% of the population are infected during their lifetime (mostly young adults); between 5% and 10% of infections lead to persistent viremia (carrier state). Certain population subgroups in these areas, however, are at high risk (see Indications and Clinical Use). In Asia, infection often occurs early in life, leading to a hepatitis B marker prevalence of more than 70% in the general population and a carrier rate of up to 20%. It is estimated that the reservoir of persistent hepatitis B surface antigen carriers amounts to 350 million people worldwide. Carriers are at a high risk of developing chronic liver disease which may lead to cirrhosis or primary hepatocellular carcinoma. A significant reduction in the incidence of hepatocellular carcinoma has been observed in children aged 6 to14 years following a nationwide hepatitis B vaccination in Taiwan. This resulted from a significant decline in the prevalence of hepatitis B antigen, the persistence of which is an essential factor in the development of hepatocellular carcinoma. Vaccination against hepatitis B is expected in the long term to reduce the overall incidence of both hepatitis B and the chronic complications such as chronic active hepatitis and cirrhosis. | Moderate | 1 | [
[
[
1555,
24,
1367
]
],
[
[
1555,
63,
1648
],
[
1648,
24,
1367
]
],
[
[
1555,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
1555,
24,
1480
],
[
1480,
24,
1367
]
],
[
[
1555,
25,
375
],
[
375,
24,
1367
]
],
[
[
1555,
24,
738
],
[
738,
63,
1367
]
],
[
[
1555,
25,
351
],
[
351,
63,
1367
]
],
[
[
1555,
63,
1648
],
[
1648,
24,
1560
],
[
1560,
24,
1367
]
],
[
[
1555,
63,
1560
],
[
1560,
63,
1648
],
[
1648,
24,
1367
]
],
[
[
1555,
64,
1064
],
[
1064,
36,
1083
],
[
1083,
24,
1367
]
]
] | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
],
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
]
] | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Oxaliplatin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Oxaliplatin may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Oxaliplatin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Oxaliplatin may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) resembles Trifluridine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant) |
DB00598 | DB08865 | 1,523 | 1,593 | [
"DDInter1013",
"DDInter448"
] | Labetalol | Crizotinib | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements. | Moderate | 1 | [
[
[
1523,
24,
1593
]
],
[
[
1523,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
1523,
40,
271
],
[
271,
62,
1593
]
],
[
[
1523,
23,
286
],
[
286,
63,
1593
]
],
[
[
1523,
25,
455
],
[
455,
24,
1593
]
],
[
[
1523,
63,
305
],
[
305,
24,
1593
]
],
[
[
1523,
24,
850
],
[
850,
63,
1593
]
],
[
[
1523,
23,
578
],
[
578,
24,
1593
]
],
[
[
1523,
24,
1419
],
[
1419,
24,
1593
]
],
[
[
1523,
40,
211
],
[
211,
24,
1593
]
]
] | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Labetalol",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Crizotinib"
]
],
[
[
"Labetalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Labetalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Labetalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Tolterodine"
],
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
]
] | Labetalol (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Labetalol (Compound) resembles Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Labetalol may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Labetalol may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Labetalol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Labetalol (Compound) resembles Tolterodine (Compound) and Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib |
DB00959 | DB01377 | 1,486 | 1,283 | [
"DDInter1191",
"DDInter1119"
] | Methylprednisolone | Magnesium oxide | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
1486,
23,
1283
]
],
[
[
1486,
63,
743
],
[
743,
23,
1283
]
],
[
[
1486,
24,
1482
],
[
1482,
62,
1283
]
],
[
[
1486,
40,
167
],
[
167,
23,
1283
]
],
[
[
1486,
24,
772
],
[
772,
23,
1283
]
],
[
[
1486,
62,
1018
],
[
1018,
23,
1283
]
],
[
[
1486,
1,
175
],
[
175,
23,
1283
]
],
[
[
1486,
25,
255
],
[
255,
63,
1283
]
],
[
[
1486,
63,
1479
],
[
1479,
24,
1283
]
],
[
[
1486,
64,
1091
],
[
1091,
24,
1283
]
]
] | [
[
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
],
[
"Lisinopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
]
] | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Methylprednisolone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Methylprednisolone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Methylprednisolone may lead to a major life threatening interaction when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Methylprednisolone may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide |
DB00668 | DB00968 | 874 | 1,551 | [
"DDInter652",
"DDInter1185"
] | Epinephrine | Methyldopa | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been available since 1987 in the USA. Many new products/biosimilars and dosage routes have been approved under various names over the last several decades,,. On August 16, 2018, Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths. Dosage delivery routes for epinephrine include intravenous, inhalation, nebulization, intramuscular injection, and subcutaneous injection. In general, the most common uses of parenteral epinephrine are to relieve respiratory distress due to | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form. First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents; however, it is still used as monotherapy or in combination with [hydrochlorothiazide]. Methyldopa is also available as intravenous injection, which is used to manage hypertension when oral therapy is unfeasible and to treat hypertensive crisis. | Moderate | 1 | [
[
[
874,
24,
1551
]
],
[
[
874,
40,
354
],
[
354,
40,
1551
]
],
[
[
874,
24,
1148
],
[
1148,
40,
1551
]
],
[
[
874,
24,
1354
],
[
1354,
1,
1551
]
],
[
[
874,
6,
5372
],
[
5372,
45,
1551
]
],
[
[
874,
7,
13230
],
[
13230,
46,
1551
]
],
[
[
874,
21,
28646
],
[
28646,
60,
1551
]
],
[
[
874,
24,
959
],
[
959,
62,
1551
]
],
[
[
874,
63,
590
],
[
590,
23,
1551
]
],
[
[
874,
25,
1264
],
[
1264,
62,
1551
]
]
] | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyldopa"
]
],
[
[
"Epinephrine",
"{u} (Compound) resembles {v} (Compound)",
"Norepinephrine"
],
[
"Norepinephrine",
"{u} (Compound) resembles {v} (Compound)",
"Methyldopa"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} (Compound) resembles {v} (Compound)",
"Methyldopa"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droxidopa"
],
[
"Droxidopa",
"{u} (Compound) resembles {v} (Compound)",
"Methyldopa"
]
],
[
[
"Epinephrine",
"{u} (Compound) binds {v} (Gene)",
"ADRA2A"
],
[
"ADRA2A",
"{u} (Gene) is bound by {v} (Compound)",
"Methyldopa"
]
],
[
[
"Epinephrine",
"{u} (Compound) upregulates {v} (Gene)",
"TIPARP"
],
[
"TIPARP",
"{u} (Gene) is upregulated by {v} (Compound)",
"Methyldopa"
]
],
[
[
"Epinephrine",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
"Unspecified disorder of skin and subcutaneous tissue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methyldopa"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methyldopa"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methyldopa"
]
],
[
[
"Epinephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methyldopa"
]
]
] | Epinephrine (Compound) resembles Norepinephrine (Compound) and Norepinephrine (Compound) resembles Methyldopa (Compound)
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline (Compound) resembles Methyldopa (Compound)
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa and Droxidopa (Compound) resembles Methyldopa (Compound)
Epinephrine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Methyldopa (Compound)
Epinephrine (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Methyldopa (Compound)
Epinephrine (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Methyldopa (Compound)
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a minor interaction that can limit clinical effects when taken with Methyldopa
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Methyldopa
Epinephrine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Methyldopa |
DB08895 | DB09065 | 976 | 760 | [
"DDInter1825",
"DDInter424"
] | Tofacitinib | Cobicistat | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile. | Major | 2 | [
[
[
976,
25,
760
]
],
[
[
976,
63,
479
],
[
479,
23,
760
]
],
[
[
976,
64,
1101
],
[
1101,
23,
760
]
],
[
[
976,
24,
555
],
[
555,
23,
760
]
],
[
[
976,
63,
875
],
[
875,
24,
760
]
],
[
[
976,
64,
34
],
[
34,
24,
760
]
],
[
[
976,
24,
1040
],
[
1040,
24,
760
]
],
[
[
976,
25,
68
],
[
68,
63,
760
]
],
[
[
976,
25,
384
],
[
384,
24,
760
]
],
[
[
976,
24,
1580
],
[
1580,
63,
760
]
]
] | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
],
[
"Netupitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosamprenavir"
],
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
]
] | Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Tofacitinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Tofacitinib may lead to a major life threatening interaction when taken with Fosamprenavir and Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Tofacitinib may lead to a major life threatening interaction when taken with Troleandomycin and Troleandomycin may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Tofacitinib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol and Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat |
DB00637 | DB08816 | 1,557 | 578 | [
"DDInter128",
"DDInter1802"
] | Astemizole | Ticagrelor | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Moderate | 1 | [
[
[
1557,
24,
578
]
],
[
[
1557,
6,
4973
],
[
4973,
45,
578
]
],
[
[
1557,
64,
17
],
[
17,
23,
578
]
],
[
[
1557,
25,
1585
],
[
1585,
23,
578
]
],
[
[
1557,
25,
1011
],
[
1011,
62,
578
]
],
[
[
1557,
25,
723
],
[
723,
24,
578
]
],
[
[
1557,
25,
868
],
[
868,
63,
578
]
],
[
[
1557,
24,
1297
],
[
1297,
63,
578
]
],
[
[
1557,
63,
1101
],
[
1101,
24,
578
]
],
[
[
1557,
24,
749
],
[
749,
24,
578
]
]
] | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Astemizole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Ticagrelor"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Adenosine"
],
[
"Adenosine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimavanserin"
],
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
]
] | Astemizole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Astemizole may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Astemizole may lead to a major life threatening interaction when taken with Adenosine and Adenosine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Astemizole may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Astemizole may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Astemizole may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Pimavanserin and Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor |
DB00655 | DB01285 | 559 | 708 | [
"DDInter682",
"DDInter445"
] | Estrone | Corticotropin | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase. | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
559,
24,
708
]
],
[
[
559,
23,
771
],
[
771,
62,
708
]
],
[
[
559,
63,
245
],
[
245,
24,
708
]
],
[
[
559,
24,
170
],
[
170,
24,
708
]
],
[
[
559,
24,
5
],
[
5,
63,
708
]
],
[
[
559,
1,
1561
],
[
1561,
24,
708
]
],
[
[
559,
1,
890
],
[
890,
63,
708
]
],
[
[
559,
40,
1438
],
[
1438,
24,
708
]
],
[
[
559,
23,
771
],
[
771,
62,
890
],
[
890,
63,
708
]
],
[
[
559,
63,
245
],
[
245,
24,
455
],
[
455,
23,
708
]
]
] | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Estrone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Corticotropin"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
],
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
],
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Estradiol"
],
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Estrone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mestranol"
],
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Corticotropin"
]
]
] | Estrone may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Estrone (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Estrone (Compound) resembles Mestranol (Compound) and Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Estrone (Compound) resembles Estradiol (Compound) and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Estrone may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Mestranol and Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin |
DB00486 | DB00876 | 1,614 | 1,414 | [
"DDInter1253",
"DDInter658"
] | Nabilone | Eprosartan | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are | Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. | Moderate | 1 | [
[
[
1614,
24,
1414
]
],
[
[
1614,
24,
240
],
[
240,
40,
1414
]
],
[
[
1614,
21,
28957
],
[
28957,
60,
1414
]
],
[
[
1614,
24,
1264
],
[
1264,
63,
1414
]
],
[
[
1614,
63,
475
],
[
475,
24,
1414
]
],
[
[
1614,
40,
530
],
[
530,
24,
1414
]
],
[
[
1614,
24,
240
],
[
240,
5,
11590
],
[
11590,
44,
1414
]
],
[
[
1614,
21,
28957
],
[
28957,
60,
240
],
[
240,
40,
1414
]
],
[
[
1614,
21,
29269
],
[
29269,
60,
1264
],
[
1264,
63,
1414
]
],
[
[
1614,
21,
28640
],
[
28640,
60,
1573
],
[
1573,
24,
1414
]
]
] | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eprosartan"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Losartan"
],
[
"Losartan",
"{u} (Compound) resembles {v} (Compound)",
"Eprosartan"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Arthralgia"
],
[
"Arthralgia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Eprosartan"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eprosartan"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eprosartan"
]
],
[
[
"Nabilone",
"{u} (Compound) resembles {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eprosartan"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Losartan"
],
[
"Losartan",
"{u} (Compound) treats {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is treated by {v} (Compound)",
"Eprosartan"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Arthralgia"
],
[
"Arthralgia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Losartan"
],
[
"Losartan",
"{u} (Compound) resembles {v} (Compound)",
"Eprosartan"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Menopausal symptoms"
],
[
"Menopausal symptoms",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eprosartan"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Depression"
],
[
"Depression",
"{u} (Side Effect) is caused by {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eprosartan"
]
]
] | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Losartan and Losartan (Compound) resembles Eprosartan (Compound)
Nabilone (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Eprosartan (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan
Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Losartan and Losartan (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Eprosartan (Compound)
Nabilone (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Losartan (Compound) and Losartan (Compound) resembles Eprosartan (Compound)
Nabilone (Compound) causes Menopausal symptoms (Side Effect) and Menopausal symptoms (Side Effect) is caused by Doxepin (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan
Nabilone (Compound) causes Depression (Side Effect) and Depression (Side Effect) is caused by Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan |
DB00563 | DB14783 | 663 | 287 | [
"DDInter1174",
"DDInter574"
] | Methotrexate | Diroximel fumarate | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021. | Moderate | 1 | [
[
[
663,
24,
287
]
],
[
[
663,
63,
1101
],
[
1101,
24,
287
]
],
[
[
663,
24,
384
],
[
384,
24,
287
]
],
[
[
663,
25,
770
],
[
770,
24,
287
]
],
[
[
663,
23,
328
],
[
328,
24,
287
]
],
[
[
663,
25,
1510
],
[
1510,
25,
287
]
],
[
[
663,
64,
1066
],
[
1066,
25,
287
]
],
[
[
663,
25,
676
],
[
676,
64,
287
]
],
[
[
663,
24,
713
],
[
713,
25,
287
]
],
[
[
663,
63,
1101
],
[
1101,
64,
1560
],
[
1560,
24,
287
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
]
] | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Methotrexate may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Methotrexate may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate
Methotrexate may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Diroximel fumarate
Methotrexate may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Diroximel fumarate
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may lead to a major life threatening interaction when taken with Diroximel fumarate
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate |
DB01365 | DB06655 | 280 | 5 | [
"DDInter1151",
"DDInter1077"
] | Mephentermine | Liraglutide | A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1248) | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010. | Moderate | 1 | [
[
[
280,
24,
5
]
],
[
[
280,
63,
245
],
[
245,
24,
5
]
],
[
[
280,
40,
1445
],
[
1445,
24,
5
]
],
[
[
280,
74,
73
],
[
73,
24,
5
]
],
[
[
280,
24,
1296
],
[
1296,
63,
5
]
],
[
[
280,
1,
22
],
[
22,
24,
5
]
],
[
[
280,
63,
245
],
[
245,
23,
1103
],
[
1103,
23,
5
]
],
[
[
280,
63,
480
],
[
480,
62,
870
],
[
870,
24,
5
]
],
[
[
280,
63,
1152
],
[
1152,
24,
1252
],
[
1252,
23,
5
]
],
[
[
280,
40,
1445
],
[
1445,
63,
1252
],
[
1252,
23,
5
]
]
] | [
[
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Mephentermine",
"{u} (Compound) resembles {v} (Compound)",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Mephentermine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Mephentermine",
"{u} (Compound) resembles {v} (Compound)",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liraglutide"
]
],
[
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liraglutide"
]
],
[
[
"Mephentermine",
"{u} (Compound) resembles {v} (Compound)",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liraglutide"
]
]
] | Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Mephentermine (Compound) resembles Pseudoephedrine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Mephentermine (Compound) resembles Phentermine (Compound) and Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Mephentermine (Compound) resembles Ephedrine (Compound) and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Mephentermine (Compound) resembles Pseudoephedrine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Liraglutide |
DB00687 | DB12332 | 870 | 1,619 | [
"DDInter747",
"DDInter1626"
] | Fludrocortisone | Rucaparib | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
870,
24,
1619
]
],
[
[
870,
23,
307
],
[
307,
23,
1619
]
],
[
[
870,
24,
259
],
[
259,
24,
1619
]
],
[
[
870,
24,
151
],
[
151,
63,
1619
]
],
[
[
870,
63,
84
],
[
84,
24,
1619
]
],
[
[
870,
25,
739
],
[
739,
24,
1619
]
],
[
[
870,
1,
1486
],
[
1486,
24,
1619
]
],
[
[
870,
23,
455
],
[
455,
24,
1619
]
],
[
[
870,
23,
1032
],
[
1032,
63,
1619
]
],
[
[
870,
25,
1259
],
[
1259,
25,
1619
]
]
] | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
],
[
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levosalbutamol"
],
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
]
] | Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) and Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Fludrocortisone may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Fludrocortisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Fludrocortisone may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Rucaparib |
DB04948 | DB08881 | 1,084 | 868 | [
"DDInter1083",
"DDInter1925"
] | Lofexidine | Vemurafenib | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine. Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. | Major | 2 | [
[
[
1084,
25,
868
]
],
[
[
1084,
62,
112
],
[
112,
23,
868
]
],
[
[
1084,
63,
480
],
[
480,
24,
868
]
],
[
[
1084,
24,
286
],
[
286,
63,
868
]
],
[
[
1084,
64,
478
],
[
478,
25,
868
]
],
[
[
1084,
24,
823
],
[
823,
64,
868
]
],
[
[
1084,
63,
1424
],
[
1424,
25,
868
]
],
[
[
1084,
24,
1250
],
[
1250,
25,
868
]
],
[
[
1084,
25,
1069
],
[
1069,
25,
868
]
],
[
[
1084,
25,
985
],
[
985,
64,
868
]
]
] | [
[
[
"Lofexidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Lofexidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vemurafenib"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Lofexidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Lofexidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Lofexidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
]
] | Lofexidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Lofexidine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Vemurafenib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may lead to a major life threatening interaction when taken with Vemurafenib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Vemurafenib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Vemurafenib
Lofexidine may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Vemurafenib
Lofexidine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Vemurafenib |
DB00009 | DB06779 | 1,271 | 365 | [
"DDInter56",
"DDInter470"
] | Alteplase | Dalteparin | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells.[A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting. However, its use for the treatment of acute ischem | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. | Major | 2 | [
[
[
1271,
25,
365
]
],
[
[
1271,
23,
539
],
[
539,
62,
365
]
],
[
[
1271,
24,
954
],
[
954,
24,
365
]
],
[
[
1271,
24,
1496
],
[
1496,
63,
365
]
],
[
[
1271,
24,
1018
],
[
1018,
25,
365
]
],
[
[
1271,
25,
256
],
[
256,
25,
365
]
],
[
[
1271,
25,
1468
],
[
1468,
64,
365
]
],
[
[
1271,
64,
1578
],
[
1578,
25,
365
]
],
[
[
1271,
24,
578
],
[
578,
64,
365
]
],
[
[
1271,
23,
539
],
[
539,
62,
1018
],
[
1018,
25,
365
]
]
] | [
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Alteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dalteparin"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalteparin"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
],
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalteparin"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Alteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
]
] | Alteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dalteparin
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Dalteparin
Alteplase may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may lead to a major life threatening interaction when taken with Dalteparin
Alteplase may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Dalteparin
Alteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Dalteparin
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Dalteparin
Alteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Dalteparin |
DB00983 | DB01232 | 480 | 1,327 | [
"DDInter776",
"DDInter1640"
] | Formoterol | Saquinavir | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351] | Moderate | 1 | [
[
[
480,
24,
1327
]
],
[
[
480,
24,
833
],
[
833,
1,
1327
]
],
[
[
480,
6,
10215
],
[
10215,
45,
1327
]
],
[
[
480,
21,
28691
],
[
28691,
60,
1327
]
],
[
[
480,
24,
222
],
[
222,
23,
1327
]
],
[
[
480,
24,
52
],
[
52,
63,
1327
]
],
[
[
480,
24,
1130
],
[
1130,
24,
1327
]
],
[
[
480,
63,
127
],
[
127,
24,
1327
]
],
[
[
480,
62,
891
],
[
891,
24,
1327
]
],
[
[
480,
23,
1220
],
[
1220,
63,
1327
]
]
] | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
]
],
[
[
"Formoterol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Saquinavir"
]
],
[
[
"Formoterol",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Saquinavir"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Saquinavir"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Formoterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Formoterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
]
] | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir and Lopinavir (Compound) resembles Saquinavir (Compound)
Formoterol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Saquinavir (Compound)
Formoterol (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Saquinavir (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Saquinavir
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir
Formoterol may cause a minor interaction that can limit clinical effects when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir
Formoterol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir |
DB08816 | DB09065 | 578 | 760 | [
"DDInter1802",
"DDInter424"
] | Ticagrelor | Cobicistat | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile. | Major | 2 | [
[
[
578,
25,
760
]
],
[
[
578,
23,
271
],
[
271,
23,
760
]
],
[
[
578,
63,
1230
],
[
1230,
23,
760
]
],
[
[
578,
23,
907
],
[
907,
62,
760
]
],
[
[
578,
24,
555
],
[
555,
23,
760
]
],
[
[
578,
63,
875
],
[
875,
24,
760
]
],
[
[
578,
24,
868
],
[
868,
24,
760
]
],
[
[
578,
64,
609
],
[
609,
24,
760
]
],
[
[
578,
25,
1421
],
[
1421,
63,
760
]
],
[
[
578,
23,
1586
],
[
1586,
63,
760
]
]
] | [
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
],
[
"Netupitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levamlodipine"
],
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
]
] | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Ticagrelor may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Ticagrelor may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Levamlodipine and Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat |
DB00382 | DB06603 | 62 | 39 | [
"DDInter1734",
"DDInter1387"
] | Tacrine | Panobinostat | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Moderate | 1 | [
[
[
62,
24,
39
]
],
[
[
62,
24,
112
],
[
112,
23,
39
]
],
[
[
62,
63,
912
],
[
912,
24,
39
]
],
[
[
62,
24,
272
],
[
272,
24,
39
]
],
[
[
62,
24,
850
],
[
850,
63,
39
]
],
[
[
62,
24,
594
],
[
594,
64,
39
]
],
[
[
62,
24,
485
],
[
485,
25,
39
]
],
[
[
62,
23,
848
],
[
848,
25,
39
]
],
[
[
62,
63,
521
],
[
521,
25,
39
]
],
[
[
62,
25,
1377
],
[
1377,
25,
39
]
]
] | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Panobinostat"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Tacrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Tacrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
]
] | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Panobinostat
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Panobinostat
Tacrine may cause a minor interaction that can limit clinical effects when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Panobinostat
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may lead to a major life threatening interaction when taken with Panobinostat
Tacrine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Panobinostat |
DB00619 | DB04938 | 1,419 | 1,423 | [
"DDInter909",
"DDInter1353"
] | Imatinib | Ospemifene | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013. | Moderate | 1 | [
[
[
1419,
24,
1423
]
],
[
[
1419,
6,
6017
],
[
6017,
45,
1423
]
],
[
[
1419,
21,
28883
],
[
28883,
60,
1423
]
],
[
[
1419,
24,
72
],
[
72,
63,
1423
]
],
[
[
1419,
25,
129
],
[
129,
63,
1423
]
],
[
[
1419,
63,
522
],
[
522,
24,
1423
]
],
[
[
1419,
35,
478
],
[
478,
24,
1423
]
],
[
[
1419,
24,
86
],
[
86,
24,
1423
]
],
[
[
1419,
63,
600
],
[
600,
25,
1423
]
],
[
[
1419,
24,
770
],
[
770,
25,
1423
]
]
] | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ospemifene"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Ospemifene"
]
],
[
[
"Imatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Skin disorder"
],
[
"Skin disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ospemifene"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
],
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ospemifene"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ospemifene"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
],
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ospemifene"
]
],
[
[
"Imatinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ospemifene"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ospemifene"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ospemifene"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ospemifene"
]
]
] | Imatinib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Ospemifene (Compound)
Imatinib (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Ospemifene (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Ospemifene
Imatinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Ospemifene
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Ospemifene
Imatinib (Compound) resembles Nilotinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ospemifene
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Ospemifene
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ospemifene
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Ospemifene |
DB05015 | DB05273 | 1,077 | 507 | [
"DDInter174",
"DDInter1638"
] | Belinostat | Samarium (153Sm) lexidronam | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma. | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain. | Major | 2 | [
[
[
1077,
25,
507
]
],
[
[
1077,
63,
248
],
[
248,
24,
507
]
],
[
[
1077,
24,
270
],
[
270,
63,
507
]
],
[
[
1077,
24,
850
],
[
850,
64,
507
]
],
[
[
1077,
64,
1064
],
[
1064,
25,
507
]
],
[
[
1077,
63,
478
],
[
478,
25,
507
]
],
[
[
1077,
25,
1259
],
[
1259,
64,
507
]
],
[
[
1077,
63,
248
],
[
248,
40,
563
],
[
563,
24,
507
]
],
[
[
1077,
63,
563
],
[
563,
1,
248
],
[
248,
24,
507
]
],
[
[
1077,
24,
270
],
[
270,
63,
196
],
[
196,
25,
507
]
]
] | [
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Altretamine"
],
[
"Altretamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
]
] | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Belinostat may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Belinostat may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound) and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound) and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Altretamine and Altretamine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam |
DB01191 | DB08893 | 1,039 | 271 | [
"DDInter518",
"DDInter1229"
] | Dexfenfluramine | Mirabegron | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significant antimuscarinic activity, which is responsible both for the therapeutic effects of these medications and their broad range of adverse effects. Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its use alongside solifenacin in refractory cases. Mirabegron first received FDA approval in 2012, under the brand name Myrbetriq, for the treatment of adults with overactive bladder. An extended-release granule formulation was subsequently granted approval in March 2021 for the treatment of pediatric patients with neurogenic detrusor overactivity. Mirabegron is also used in other jurisdictions across the globe, including Canada, the EU, and Japan. | Moderate | 1 | [
[
[
1039,
24,
271
]
],
[
[
1039,
6,
12523
],
[
12523,
45,
271
]
],
[
[
1039,
24,
283
],
[
283,
62,
271
]
],
[
[
1039,
24,
868
],
[
868,
23,
271
]
],
[
[
1039,
63,
1419
],
[
1419,
23,
271
]
],
[
[
1039,
24,
1311
],
[
1311,
24,
271
]
],
[
[
1039,
64,
121
],
[
121,
24,
271
]
],
[
[
1039,
64,
888
],
[
888,
25,
271
]
],
[
[
1039,
24,
1670
],
[
1670,
64,
271
]
],
[
[
1039,
6,
12523
],
[
12523,
45,
371
],
[
371,
40,
271
]
]
] | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirabegron"
]
],
[
[
"Dexfenfluramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Mirabegron"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirabegron"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirabegron"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mirabegron"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mirabegron"
]
],
[
[
"Dexfenfluramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Propafenone"
],
[
"Propafenone",
"{u} (Compound) resembles {v} (Compound)",
"Mirabegron"
]
]
] | Dexfenfluramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mirabegron (Compound)
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron
Dexfenfluramine may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron
Dexfenfluramine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Mirabegron
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may lead to a major life threatening interaction when taken with Mirabegron
Dexfenfluramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Propafenone (Compound) and Propafenone (Compound) resembles Mirabegron (Compound) |
DB00987 | DB01073 | 1,224 | 1,488 | [
"DDInter461",
"DDInter745"
] | Cytarabine (liposomal) | Fludarabine | Cytarabine can cause developmental toxicity according to an independent committee of scientific and health experts. | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Moderate | 1 | [
[
[
1224,
35,
1488
]
],
[
[
1224,
40,
1049
],
[
1049,
1,
1488
]
],
[
[
1224,
1,
325
],
[
325,
1,
1488
]
],
[
[
1224,
74,
372
],
[
372,
1,
1488
]
],
[
[
1224,
5,
11555
],
[
11555,
44,
1488
]
],
[
[
1224,
6,
2104
],
[
2104,
45,
1488
]
],
[
[
1224,
62,
839
],
[
839,
23,
1488
]
],
[
[
1224,
23,
1539
],
[
1539,
62,
1488
]
],
[
[
1224,
23,
956
],
[
956,
23,
1488
]
],
[
[
1224,
63,
1253
],
[
1253,
24,
1488
]
]
] | [
[
[
"Cytarabine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Cytarabine",
"{u} (Compound) resembles {v} (Compound)",
"Regadenoson"
],
[
"Regadenoson",
"{u} (Compound) resembles {v} (Compound)",
"Fludarabine"
]
],
[
[
"Cytarabine",
"{u} (Compound) resembles {v} (Compound)",
"Nelarabine"
],
[
"Nelarabine",
"{u} (Compound) resembles {v} (Compound)",
"Fludarabine"
]
],
[
[
"Cytarabine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} (Compound) resembles {v} (Compound)",
"Fludarabine"
]
],
[
[
"Cytarabine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Fludarabine"
]
],
[
[
"Cytarabine",
"{u} (Compound) binds {v} (Gene)",
"POLA1"
],
[
"POLA1",
"{u} (Gene) is bound by {v} (Compound)",
"Fludarabine"
]
],
[
[
"Cytarabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludarabine"
]
],
[
[
"Cytarabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludarabine"
]
],
[
[
"Cytarabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludarabine"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palifermin"
],
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
]
] | Cytarabine (Compound) resembles Fludarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine
Cytarabine (Compound) resembles Regadenoson (Compound) and Regadenoson (Compound) resembles Fludarabine (Compound)
Cytarabine (Compound) resembles Nelarabine (Compound) and Nelarabine (Compound) resembles Fludarabine (Compound)
Cytarabine (Compound) resembles Clofarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) resembles Fludarabine (Compound)
Cytarabine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Fludarabine (Compound)
Cytarabine (Compound) binds POLA1 (Gene) and POLA1 (Gene) is bound by Fludarabine (Compound)
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin and Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Ofloxacin and Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine
Cytarabine may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine |
DB01069 | DB01268 | 401 | 1,151 | [
"DDInter1533",
"DDInter1731"
] | Promethazine | Sunitinib | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Moderate | 1 | [
[
[
401,
24,
1151
]
],
[
[
401,
25,
1311
],
[
1311,
1,
1151
]
],
[
[
401,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
401,
21,
28653
],
[
28653,
60,
1151
]
],
[
[
401,
62,
1247
],
[
1247,
23,
1151
]
],
[
[
401,
63,
1148
],
[
1148,
24,
1151
]
],
[
[
401,
24,
1250
],
[
1250,
63,
1151
]
],
[
[
401,
24,
819
],
[
819,
24,
1151
]
],
[
[
401,
64,
675
],
[
675,
24,
1151
]
],
[
[
401,
74,
216
],
[
216,
24,
1151
]
]
] | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} (Compound) resembles {v} (Compound)",
"Sunitinib"
]
],
[
[
"Promethazine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Promethazine",
"{u} (Compound) causes {v} (Side Effect)",
"Bradycardia"
],
[
"Bradycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sunitinib"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Promethazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
]
] | Promethazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide (Compound) resembles Sunitinib (Compound)
Promethazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Promethazine (Compound) causes Bradycardia (Side Effect) and Bradycardia (Side Effect) is caused by Sunitinib (Compound)
Promethazine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Promethazine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Promethazine (Compound) resembles Chlorpromazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib |
DB01246 | DB08822 | 820 | 911 | [
"DDInter45",
"DDInter156"
] | Alimemazine | Azilsartan medoxomil | A phenothiazine derivative that is used as an antipruritic. | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011. Many guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting enzyme (ACE) inhibitors that are also used as first-line treatment for hypertension. Azilsartan medoxomil is marketed under the brand name Edarbi. It is used to treat hypertension as monotherapy or in combination with other antihypertensive drugs. It is also available in a combination product with [chlorthalidone]. As hypertension is a major risk factor for cardiovascular disease, early management of hypertension has several implications on patients' survival rate and quality of life in the future. Lowering blood pressure is associated with a reduced risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil is thus speculated to lower mortality rates and the onset of cardiovascular disease. Although there is no clinical significance yet determined, azilsartan medoxomil may have potential off-label uses in patients with a history of myocardial infarction or heart failure. | Moderate | 1 | [
[
[
820,
24,
911
]
],
[
[
820,
63,
217
],
[
217,
1,
911
]
],
[
[
820,
21,
28680
],
[
28680,
60,
911
]
],
[
[
820,
24,
1450
],
[
1450,
63,
911
]
],
[
[
820,
24,
549
],
[
549,
24,
911
]
],
[
[
820,
63,
1614
],
[
1614,
24,
911
]
],
[
[
820,
74,
1264
],
[
1264,
24,
911
]
],
[
[
820,
64,
593
],
[
593,
24,
911
]
],
[
[
820,
1,
104
],
[
104,
24,
911
]
],
[
[
820,
64,
1621
],
[
1621,
25,
911
]
]
] | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesartan"
],
[
"Olmesartan",
"{u} (Compound) resembles {v} (Compound)",
"Azilsartan medoxomil"
]
],
[
[
"Alimemazine",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Azilsartan medoxomil"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Azilsartan medoxomil"
]
]
] | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Alimemazine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Azilsartan medoxomil (Compound)
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Alimemazine (Compound) resembles Doxepin (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Alimemazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Alimemazine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Alimemazine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Azilsartan medoxomil |
DB00468 | DB12141 | 1,424 | 971 | [
"DDInter1557",
"DDInter817"
] | Quinine | Gilteritinib | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status. | Moderate | 1 | [
[
[
1424,
24,
971
]
],
[
[
1424,
23,
1135
],
[
1135,
23,
971
]
],
[
[
1424,
24,
485
],
[
485,
24,
971
]
],
[
[
1424,
24,
730
],
[
730,
63,
971
]
],
[
[
1424,
63,
1023
],
[
1023,
24,
971
]
],
[
[
1424,
64,
1181
],
[
1181,
24,
971
]
],
[
[
1424,
25,
1339
],
[
1339,
63,
971
]
],
[
[
1424,
62,
529
],
[
529,
24,
971
]
],
[
[
1424,
25,
1250
],
[
1250,
24,
971
]
],
[
[
1424,
23,
752
],
[
752,
24,
971
]
]
] | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gilteritinib"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
],
[
"Deutetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
],
[
"Berotralstat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
]
] | Quinine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine and Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Quinine may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Quinine may lead to a major life threatening interaction when taken with Berotralstat and Berotralstat may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Quinine may cause a minor interaction that can limit clinical effects when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Quinine may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Quinine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib |
DB00361 | DB11989 | 134 | 1,434 | [
"DDInter1939",
"DDInter183"
] | Vinorelbine | Benznidazole | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug. | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
134,
24,
1434
]
],
[
[
134,
24,
788
],
[
788,
24,
1434
]
],
[
[
134,
25,
375
],
[
375,
24,
1434
]
],
[
[
134,
24,
148
],
[
148,
63,
1434
]
],
[
[
134,
64,
581
],
[
581,
24,
1434
]
],
[
[
134,
63,
1451
],
[
1451,
24,
1434
]
],
[
[
134,
25,
1091
],
[
1091,
25,
1434
]
],
[
[
134,
24,
788
],
[
788,
24,
375
],
[
375,
24,
1434
]
],
[
[
134,
25,
375
],
[
375,
63,
788
],
[
788,
24,
1434
]
],
[
[
134,
24,
148
],
[
148,
63,
788
],
[
788,
24,
1434
]
]
] | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
],
[
"Secnidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfa-n1"
],
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Benznidazole"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
],
[
"Secnidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
]
] | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Vinorelbine may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Vinorelbine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfa-n1 and Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Vinorelbine may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may lead to a major life threatening interaction when taken with Benznidazole
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Vinorelbine may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole |
DB00277 | DB00349 | 1,031 | 902 | [
"DDInter1791",
"DDInter401"
] | Theophylline | Clobazam | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD. | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike older 1,4-benzodiazepines, clobazam has a better side-effects profile, particularly less sedative and amnesic effects.[A256963,A256868] This is likely because of clobazam's higher affinity to the α<sub>2</sub> subunit of the GABA<sub>A</sub> receptor, which mediates anxiolytic effects, than the α<sub>1</sub> subunit, which mediates sedative effect. Additionally, clobazam is believed to be a partial agonist to the GABA<sub>A</sub> receptor rather than non-selective full receptor agonists like 1,4-benzodiazepines, thus potentially explaining the decreased incidence of sedative effects.[A256968,A256973] Clobazam has been marketed as an anxiolytic since 1975 and an anticonvulsant since 1984.[A521,A522] In October 21, 2011, the FDA approved clobazam as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in adults and children aged two years and older. In 2005, clobazam also received approval from Health Canada as an add-on therapy for generalized tonic-clonic, myoclonic, and focal impaired awareness seizures. | Minor | 0 | [
[
[
1031,
23,
902
]
],
[
[
1031,
23,
1382
],
[
1382,
1,
902
]
],
[
[
1031,
62,
1174
],
[
1174,
1,
902
]
],
[
[
1031,
6,
8374
],
[
8374,
45,
902
]
],
[
[
1031,
21,
28658
],
[
28658,
60,
902
]
],
[
[
1031,
1,
746
],
[
746,
62,
902
]
],
[
[
1031,
24,
1303
],
[
1303,
63,
902
]
],
[
[
1031,
63,
1057
],
[
1057,
24,
902
]
],
[
[
1031,
25,
593
],
[
593,
63,
902
]
],
[
[
1031,
23,
1215
],
[
1215,
63,
902
]
]
] | [
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clobazam"
]
],
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Midazolam"
],
[
"Midazolam",
"{u} (Compound) resembles {v} (Compound)",
"Clobazam"
]
],
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Temazepam"
],
[
"Temazepam",
"{u} (Compound) resembles {v} (Compound)",
"Clobazam"
]
],
[
[
"Theophylline",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Clobazam"
]
],
[
[
"Theophylline",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clobazam"
]
],
[
[
"Theophylline",
"{u} (Compound) resembles {v} (Compound)",
"Dyphylline"
],
[
"Dyphylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clobazam"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
],
[
"Guselkumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
]
],
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
]
],
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
]
]
] | Theophylline may cause a minor interaction that can limit clinical effects when taken with Midazolam and Midazolam (Compound) resembles Clobazam (Compound)
Theophylline may cause a minor interaction that can limit clinical effects when taken with Temazepam and Temazepam (Compound) resembles Clobazam (Compound)
Theophylline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clobazam (Compound)
Theophylline (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Clobazam (Compound)
Theophylline (Compound) resembles Dyphylline (Compound) and Dyphylline may cause a minor interaction that can limit clinical effects when taken with Clobazam
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab and Guselkumab may cause a moderate interaction that could exacerbate diseases when taken with Clobazam
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Clobazam
Theophylline may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Clobazam
Theophylline may cause a minor interaction that can limit clinical effects when taken with Lansoprazole and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Clobazam |
DB00836 | DB01611 | 543 | 1,487 | [
"DDInter1088",
"DDInter893"
] | Loperamide | Hydroxychloroquine | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxylate] and [haloperidol]. Due to pharmacological properties, loperamide has been misused and abused to self-manage opioid withdrawal symptoms and to induce euphoria.[A251610, A251625] However, loperamide is associated with a risk for experiencing a range of adverse effects, often life-threatening, if taking for non-therapeutic reasons or at doses higher than the recommended dose. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.** Hydroxychloroquine was granted FDA approval on 18 April 1955. A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19. | Moderate | 1 | [
[
[
543,
24,
1487
]
],
[
[
543,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
543,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
543,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
543,
24,
211
],
[
211,
23,
1487
]
],
[
[
543,
24,
1623
],
[
1623,
63,
1487
]
],
[
[
543,
63,
521
],
[
521,
24,
1487
]
],
[
[
543,
64,
441
],
[
441,
24,
1487
]
],
[
[
543,
24,
688
],
[
688,
24,
1487
]
],
[
[
543,
25,
915
],
[
915,
24,
1487
]
]
] | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Loperamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Hydroxychloroquine"
]
],
[
[
"Loperamide",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydroxychloroquine"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
],
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Loperamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Loperamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
]
] | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Loperamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Loperamide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Hydroxychloroquine
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium and Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Loperamide may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Loperamide may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine |
DB00877 | DB09322 | 629 | 1,114 | [
"DDInter1678",
"DDInter1966"
] | Sirolimus | Zinc sulfate | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Minor | 0 | [
[
[
629,
23,
1114
]
],
[
[
629,
63,
66
],
[
66,
23,
1114
]
],
[
[
629,
24,
1093
],
[
1093,
62,
1114
]
],
[
[
629,
64,
1057
],
[
1057,
23,
1114
]
],
[
[
629,
24,
259
],
[
259,
23,
1114
]
],
[
[
629,
25,
908
],
[
908,
23,
1114
]
],
[
[
629,
25,
676
],
[
676,
62,
1114
]
],
[
[
629,
64,
1199
],
[
1199,
24,
1114
]
],
[
[
629,
63,
839
],
[
839,
24,
1114
]
],
[
[
629,
24,
943
],
[
943,
63,
1114
]
]
] | [
[
[
"Sirolimus",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibandronate"
],
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc sulfate"
]
]
] | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Sirolimus may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Sirolimus may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Sirolimus may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Sirolimus may lead to a major life threatening interaction when taken with Ibandronate and Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Zinc sulfate
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Zinc sulfate
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Zinc sulfate |
DB01030 | DB04865 | 869 | 4 | [
"DDInter1835",
"DDInter1335"
] | Topotecan | Omacetaxine mepesuccinate | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. | Moderate | 1 | [
[
[
869,
24,
4
]
],
[
[
869,
7,
14560
],
[
14560,
46,
4
]
],
[
[
869,
18,
5106
],
[
5106,
46,
4
]
],
[
[
869,
7,
3519
],
[
3519,
57,
4
]
],
[
[
869,
18,
1917
],
[
1917,
57,
4
]
],
[
[
869,
63,
1394
],
[
1394,
24,
4
]
],
[
[
869,
25,
770
],
[
770,
24,
4
]
],
[
[
869,
24,
496
],
[
496,
63,
4
]
],
[
[
869,
64,
589
],
[
589,
24,
4
]
],
[
[
869,
24,
1532
],
[
1532,
24,
4
]
]
] | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Topotecan",
"{u} (Compound) upregulates {v} (Gene)",
"STAP2"
],
[
"STAP2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Omacetaxine mepesuccinate"
]
],
[
[
"Topotecan",
"{u} (Compound) downregulates {v} (Gene)",
"ARID4B"
],
[
"ARID4B",
"{u} (Gene) is upregulated by {v} (Compound)",
"Omacetaxine mepesuccinate"
]
],
[
[
"Topotecan",
"{u} (Compound) upregulates {v} (Gene)",
"TMEM230"
],
[
"TMEM230",
"{u} (Gene) is downregulated by {v} (Compound)",
"Omacetaxine mepesuccinate"
]
],
[
[
"Topotecan",
"{u} (Compound) downregulates {v} (Gene)",
"CDC25B"
],
[
"CDC25B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Omacetaxine mepesuccinate"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rituximab"
],
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
]
] | Topotecan (Compound) upregulates STAP2 (Gene) and STAP2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Topotecan (Compound) downregulates ARID4B (Gene) and ARID4B (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Topotecan (Compound) upregulates TMEM230 (Gene) and TMEM230 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Topotecan (Compound) downregulates CDC25B (Gene) and CDC25B (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Rituximab and Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Topotecan may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Topotecan may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate |
DB00491 | DB01364 | 127 | 22 | [
"DDInter1217",
"DDInter650"
] | Miglitol | Ephedrine | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. Miglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia. Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys. | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepinephrine from sympathetic neurons, inhibiting norepinephrine reuptake and displacing more norepinephrine from storage vesicles.[A193650,L12972] Ephedrine is used for its vasoconstrictive, positive chronotropic, and positive inotropic effects. Ephedrine and [phenylephrine] are still used to treat hypotension, but their use in other indications has decreased due to the development of more selective adrenergic agonists.[A193701,A193704,L12975] Ephedrine was granted a type 7 FDA Approval on 29 April 2016. | Moderate | 1 | [
[
[
127,
24,
22
]
],
[
[
127,
24,
1529
],
[
1529,
63,
22
]
],
[
[
127,
24,
280
],
[
280,
1,
22
]
],
[
[
127,
21,
28680
],
[
28680,
60,
22
]
],
[
[
127,
24,
1220
],
[
1220,
23,
22
]
],
[
[
127,
24,
959
],
[
959,
24,
22
]
],
[
[
127,
63,
508
],
[
508,
24,
22
]
],
[
[
127,
24,
222
],
[
222,
25,
22
]
],
[
[
127,
63,
73
],
[
73,
35,
22
]
],
[
[
127,
24,
1529
],
[
1529,
1,
80
],
[
80,
24,
22
]
]
] | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
],
[
"Mephentermine",
"{u} (Compound) resembles {v} (Compound)",
"Ephedrine"
]
],
[
[
"Miglitol",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ephedrine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ephedrine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ephedrine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Amphetamine"
],
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
]
] | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and Mephentermine (Compound) resembles Ephedrine (Compound)
Miglitol (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Ephedrine (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Ephedrine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Ephedrine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) resembles Ephedrine (Compound) and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Amphetamine (Compound) and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine |
DB00819 | DB01067 | 471 | 959 | [
"DDInter15",
"DDInter826"
] | Acetazolamide | Glipizide | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®. | Moderate | 1 | [
[
[
471,
24,
959
]
],
[
[
471,
63,
245
],
[
245,
40,
959
]
],
[
[
471,
24,
1411
],
[
1411,
1,
959
]
],
[
[
471,
6,
8374
],
[
8374,
45,
959
]
],
[
[
471,
21,
29091
],
[
29091,
60,
959
]
],
[
[
471,
24,
1220
],
[
1220,
63,
959
]
],
[
[
471,
63,
1674
],
[
1674,
24,
959
]
],
[
[
471,
25,
1479
],
[
1479,
24,
959
]
],
[
[
471,
64,
1645
],
[
1645,
24,
959
]
],
[
[
471,
24,
455
],
[
455,
24,
959
]
]
] | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
]
],
[
[
"Acetazolamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Glipizide"
]
],
[
[
"Acetazolamide",
"{u} (Compound) causes {v} (Side Effect)",
"Aplastic anaemia"
],
[
"Aplastic anaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Glipizide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Acetazolamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Acetazolamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
]
] | Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
Acetazolamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Glipizide (Compound)
Acetazolamide (Compound) causes Aplastic anaemia (Side Effect) and Aplastic anaemia (Side Effect) is caused by Glipizide (Compound)
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Acetazolamide may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Acetazolamide may lead to a major life threatening interaction when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide |
DB00757 | DB01035 | 1,166 | 1,401 | [
"DDInter581",
"DDInter1524"
] | Dolasetron | Procainamide | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors. | A derivative of procaine with less CNS action. | Major | 2 | [
[
[
1166,
25,
1401
]
],
[
[
1166,
6,
12523
],
[
12523,
45,
1401
]
],
[
[
1166,
21,
29081
],
[
29081,
60,
1401
]
],
[
[
1166,
23,
112
],
[
112,
23,
1401
]
],
[
[
1166,
24,
770
],
[
770,
63,
1401
]
],
[
[
1166,
24,
480
],
[
480,
24,
1401
]
],
[
[
1166,
62,
752
],
[
752,
24,
1401
]
],
[
[
1166,
63,
355
],
[
355,
24,
1401
]
],
[
[
1166,
25,
982
],
[
982,
64,
1401
]
],
[
[
1166,
64,
888
],
[
888,
25,
1401
]
]
] | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procainamide"
]
],
[
[
"Dolasetron",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Procainamide"
]
],
[
[
"Dolasetron",
"{u} (Compound) causes {v} (Side Effect)",
"Angioedema"
],
[
"Angioedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Procainamide"
]
],
[
[
"Dolasetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Procainamide"
]
],
[
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Dolasetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procainamide"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procainamide"
]
]
] | Dolasetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Procainamide (Compound)
Dolasetron (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Procainamide (Compound)
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Procainamide
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Dolasetron may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Procainamide
Dolasetron may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Procainamide |
DB00500 | DB01234 | 24 | 1,220 | [
"DDInter1831",
"DDInter513"
] | Tolmetin | Dexamethasone | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Moderate | 1 | [
[
[
24,
24,
1220
]
],
[
[
24,
24,
870
],
[
870,
1,
1220
]
],
[
[
24,
24,
175
],
[
175,
40,
1220
]
],
[
[
24,
63,
251
],
[
251,
1,
1220
]
],
[
[
24,
10,
11591
],
[
11591,
44,
1220
]
],
[
[
24,
6,
7720
],
[
7720,
45,
1220
]
],
[
[
24,
7,
3727
],
[
3727,
46,
1220
]
],
[
[
24,
21,
28882
],
[
28882,
60,
1220
]
],
[
[
24,
63,
1018
],
[
1018,
23,
1220
]
],
[
[
24,
24,
959
],
[
959,
24,
1220
]
]
] | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Tolmetin",
"{u} (Compound) palliates {v} (Disease)",
"ankylosing spondylitis"
],
[
"ankylosing spondylitis",
"{u} (Disease) is treated by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Tolmetin",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Tolmetin",
"{u} (Compound) upregulates {v} (Gene)",
"MAL"
],
[
"MAL",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Tolmetin",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
]
] | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Dexamethasone (Compound)
Tolmetin (Compound) palliates ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) is treated by Dexamethasone (Compound)
Tolmetin (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Dexamethasone (Compound)
Tolmetin (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Dexamethasone (Compound)
Tolmetin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dexamethasone (Compound)
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone |
DB05578 | DB06441 | 330 | 936 | [
"DDInter1566",
"DDInter283"
] | Ramucirumab | Cangrelor | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Ramucir | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application. | Major | 2 | [
[
[
330,
25,
936
]
],
[
[
330,
64,
97
],
[
97,
24,
936
]
],
[
[
330,
63,
383
],
[
383,
24,
936
]
],
[
[
330,
24,
643
],
[
643,
63,
936
]
],
[
[
330,
76,
1274
],
[
1274,
24,
936
]
],
[
[
330,
64,
1271
],
[
1271,
25,
936
]
],
[
[
330,
25,
1047
],
[
1047,
25,
936
]
],
[
[
330,
25,
802
],
[
802,
64,
936
]
],
[
[
330,
64,
97
],
[
97,
24,
477
],
[
477,
24,
936
]
],
[
[
330,
63,
383
],
[
383,
24,
477
],
[
477,
24,
936
]
]
] | [
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaprozin"
],
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alteplase"
],
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
],
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaprozin"
],
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
]
] | Ramucirumab may lead to a major life threatening interaction when taken with Oxaprozin and Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Ramucirumab may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Ramucirumab may lead to a major life threatening interaction when taken with Alteplase and Alteplase may lead to a major life threatening interaction when taken with Cangrelor
Ramucirumab may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzumab emtansine may lead to a major life threatening interaction when taken with Cangrelor
Ramucirumab may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may lead to a major life threatening interaction when taken with Cangrelor
Ramucirumab may lead to a major life threatening interaction when taken with Oxaprozin and Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor |
DB00092 | DB00564 | 58 | 1,236 | [
"DDInter40",
"DDInter293"
] | Alefacept | Carbamazepine | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder. | Moderate | 1 | [
[
[
58,
24,
1236
]
],
[
[
58,
24,
362
],
[
362,
1,
1236
]
],
[
[
58,
24,
1101
],
[
1101,
23,
1236
]
],
[
[
58,
63,
599
],
[
599,
24,
1236
]
],
[
[
58,
24,
250
],
[
250,
63,
1236
]
],
[
[
58,
24,
322
],
[
322,
24,
1236
]
],
[
[
58,
24,
1480
],
[
1480,
64,
1236
]
],
[
[
58,
25,
1377
],
[
1377,
64,
1236
]
],
[
[
58,
25,
1064
],
[
1064,
25,
1236
]
],
[
[
58,
24,
168
],
[
168,
25,
1236
]
]
] | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Carbamazepine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Carbamazepine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
],
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carbamazepine"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carbamazepine"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carbamazepine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carbamazepine"
]
]
] | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Carbamazepine (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Carbamazepine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab and Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may lead to a major life threatening interaction when taken with Carbamazepine
Alefacept may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Carbamazepine
Alefacept may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Carbamazepine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may lead to a major life threatening interaction when taken with Carbamazepine |
DB01128 | DB06077 | 918 | 879 | [
"DDInter204",
"DDInter1102"
] | Bicalutamide | Lumateperone | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the treatment of schizophrenia. It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology of schizophrenia.[A189093,A189174] The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia. Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. Both characteristics lend to a more favourable adverse effect profile and ultimately safer drug.[A189093,L10908] | Moderate | 1 | [
[
[
918,
24,
879
]
],
[
[
918,
24,
214
],
[
214,
63,
879
]
],
[
[
918,
24,
392
],
[
392,
24,
879
]
],
[
[
918,
63,
629
],
[
629,
24,
879
]
],
[
[
918,
25,
478
],
[
478,
24,
879
]
],
[
[
918,
63,
600
],
[
600,
25,
879
]
],
[
[
918,
25,
982
],
[
982,
64,
879
]
],
[
[
918,
1,
129
],
[
129,
64,
879
]
],
[
[
918,
24,
384
],
[
384,
64,
879
]
],
[
[
918,
24,
609
],
[
609,
25,
879
]
]
] | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumateperone"
]
],
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumateperone"
]
],
[
[
"Bicalutamide",
"{u} (Compound) resembles {v} (Compound)",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumateperone"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumateperone"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumateperone"
]
]
] | Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Bicalutamide may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Lumateperone
Bicalutamide may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Lumateperone
Bicalutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Lumateperone
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Lumateperone
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Lumateperone |
DB00024 | DB01124 | 818 | 1,411 | [
"DDInter1800",
"DDInter1828"
] | Thyrotropin alfa | Tolbutamide | Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The beta subunit (TSHB) best | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. | Moderate | 1 | [
[
[
818,
24,
1411
]
],
[
[
818,
24,
959
],
[
959,
40,
1411
]
],
[
[
818,
24,
1296
],
[
1296,
63,
1411
]
],
[
[
818,
24,
1685
],
[
1685,
24,
1411
]
],
[
[
818,
24,
959
],
[
959,
40,
694
],
[
694,
1,
1411
]
],
[
[
818,
24,
245
],
[
245,
1,
11499
],
[
11499,
40,
1411
]
],
[
[
818,
24,
1296
],
[
1296,
63,
959
],
[
959,
40,
1411
]
],
[
[
818,
24,
1685
],
[
1685,
24,
959
],
[
959,
40,
1411
]
],
[
[
818,
24,
473
],
[
473,
5,
11640
],
[
11640,
44,
1411
]
],
[
[
818,
24,
245
],
[
245,
40,
959
],
[
959,
40,
1411
]
]
] | [
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolazamide"
],
[
"Tolazamide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Glisoxepide"
],
[
"Glisoxepide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} (Compound) treats {v} (Disease)",
"type 2 diabetes mellitus"
],
[
"type 2 diabetes mellitus",
"{u} (Disease) is treated by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Thyrotropin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
]
] | Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolazamide (Compound) and Tolazamide (Compound) resembles Tolbutamide (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glisoxepide (Compound) and Glisoxepide (Compound) resembles Tolbutamide (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Tolbutamide (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide (Compound) resembles Tolbutamide (Compound) |
DB01041 | DB06700 | 770 | 643 | [
"DDInter1789",
"DDInter511"
] | Thalidomide | Desvenlafaxine | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. Although the exact mechanism of pathophysiology is still unknown, imbalances or deficiencies of monoamines have been heavily implicated, thus the rationale behind the use of SNRI to treat MDD. Desvenlafaxine has a very similar pharmacological, efficacy, and safety profile as [venlafaxine]. The major difference is the potential for drug interaction since venlafaxine is mainly metabolized by CYP2D6 while desvenlafaxine is conjugated by UGT; therefore, desvenlafaxine is less likely to cause drug-drug interaction when taken with medications affecting the CYP2D6 pathway. | Moderate | 1 | [
[
[
770,
24,
643
]
],
[
[
770,
63,
1100
],
[
1100,
1,
643
]
],
[
[
770,
21,
28709
],
[
28709,
60,
643
]
],
[
[
770,
63,
752
],
[
752,
23,
643
]
],
[
[
770,
24,
1311
],
[
1311,
24,
643
]
],
[
[
770,
64,
1648
],
[
1648,
24,
643
]
],
[
[
770,
25,
397
],
[
397,
63,
643
]
],
[
[
770,
63,
530
],
[
530,
24,
643
]
],
[
[
770,
24,
1662
],
[
1662,
63,
643
]
],
[
[
770,
25,
1532
],
[
1532,
24,
643
]
]
] | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Desvenlafaxine"
]
],
[
[
"Thalidomide",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Desvenlafaxine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Plicamycin"
],
[
"Plicamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
]
] | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Thalidomide (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Desvenlafaxine (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Desvenlafaxine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Thalidomide may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Thalidomide may lead to a major life threatening interaction when taken with Plicamycin and Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Thalidomide may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine |
DB01592 | DB12455 | 1,596 | 933 | [
"DDInter975",
"DDInter1336"
] | Iron | Omadacycline | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia. | Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings. | Moderate | 1 | [
[
[
1596,
24,
933
]
],
[
[
1596,
24,
1606
],
[
1606,
24,
933
]
],
[
[
1596,
23,
1114
],
[
1114,
24,
933
]
],
[
[
1596,
63,
1283
],
[
1283,
24,
933
]
],
[
[
1596,
24,
1606
],
[
1606,
24,
428
],
[
428,
63,
933
]
],
[
[
1596,
24,
1384
],
[
1384,
63,
417
],
[
417,
24,
933
]
],
[
[
1596,
23,
1114
],
[
1114,
23,
428
],
[
428,
63,
933
]
],
[
[
1596,
63,
1283
],
[
1283,
63,
544
],
[
544,
24,
933
]
],
[
[
1596,
21,
29196
],
[
29196,
60,
803
],
[
803,
24,
933
]
],
[
[
1596,
63,
1283
],
[
1283,
24,
853
],
[
853,
24,
933
]
]
] | [
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
],
[
"Lanthanum carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Iron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
],
[
"Lanthanum carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
],
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Iron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Iron",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Calcium chloride"
],
[
"Calcium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
],
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
]
] | Iron may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate and Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Iron may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Iron may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Iron may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate and Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Iron may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Iron may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Iron may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Iron (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Calcium chloride (Compound) and Calcium chloride may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
Iron may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride and Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline |
DB00196 | DB05239 | 600 | 866 | [
"DDInter743",
"DDInter425"
] | Fluconazole | Cobimetinib | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose. | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. | Major | 2 | [
[
[
600,
25,
866
]
],
[
[
600,
24,
214
],
[
214,
63,
866
]
],
[
[
600,
24,
888
],
[
888,
24,
866
]
],
[
[
600,
25,
1478
],
[
1478,
63,
866
]
],
[
[
600,
25,
33
],
[
33,
24,
866
]
],
[
[
600,
23,
1101
],
[
1101,
24,
866
]
],
[
[
600,
23,
1627
],
[
1627,
63,
866
]
],
[
[
600,
63,
912
],
[
912,
24,
866
]
],
[
[
600,
24,
1419
],
[
1419,
25,
866
]
],
[
[
600,
24,
1580
],
[
1580,
64,
866
]
]
] | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
]
] | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Fluconazole may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Fluconazole may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Cobimetinib
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol and Stiripentol may lead to a major life threatening interaction when taken with Cobimetinib |
DB00539 | DB00697 | 11 | 876 | [
"DDInter1837",
"DDInter1821"
] | Toremifene | Tizanidine | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label]. | Major | 2 | [
[
[
11,
25,
876
]
],
[
[
11,
6,
7950
],
[
7950,
45,
876
]
],
[
[
11,
18,
10780
],
[
10780,
57,
876
]
],
[
[
11,
21,
28748
],
[
28748,
60,
876
]
],
[
[
11,
23,
112
],
[
112,
62,
876
]
],
[
[
11,
25,
401
],
[
401,
63,
876
]
],
[
[
11,
1,
649
],
[
649,
63,
876
]
],
[
[
11,
24,
480
],
[
480,
63,
876
]
],
[
[
11,
64,
1424
],
[
1424,
24,
876
]
],
[
[
11,
35,
543
],
[
543,
63,
876
]
]
] | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Tizanidine"
]
],
[
[
"Toremifene",
"{u} (Compound) downregulates {v} (Gene)",
"CCNB2"
],
[
"CCNB2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Tizanidine"
]
],
[
[
"Toremifene",
"{u} (Compound) causes {v} (Side Effect)",
"Vertigo"
],
[
"Vertigo",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tizanidine"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tizanidine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
]
] | Toremifene (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Tizanidine (Compound)
Toremifene (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Tizanidine (Compound)
Toremifene (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Tizanidine (Compound)
Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tizanidine
Toremifene may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Toremifene (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Toremifene may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Toremifene (Compound) resembles Loperamide (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine |
DB00860 | DB01125 | 891 | 279 | [
"DDInter1513",
"DDInter98"
] | Prednisolone | Anisindione | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver. | Moderate | 1 | [
[
[
891,
24,
279
]
],
[
[
891,
63,
1647
],
[
1647,
23,
279
]
],
[
[
891,
24,
913
],
[
913,
63,
279
]
],
[
[
891,
1,
175
],
[
175,
24,
279
]
],
[
[
891,
63,
1645
],
[
1645,
24,
279
]
],
[
[
891,
25,
593
],
[
593,
63,
279
]
],
[
[
891,
40,
1220
],
[
1220,
63,
279
]
],
[
[
891,
24,
1517
],
[
1517,
24,
279
]
],
[
[
891,
62,
1018
],
[
1018,
24,
279
]
],
[
[
891,
40,
167
],
[
167,
24,
279
]
]
] | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Anisindione"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
],
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
]
] | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Anisindione
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Prednisolone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Prednisolone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Prednisolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Prednisolone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Anisindione |
DB00983 | DB01254 | 480 | 1,213 | [
"DDInter776",
"DDInter484"
] | Formoterol | Dasatinib | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] | Moderate | 1 | [
[
[
480,
24,
1213
]
],
[
[
480,
18,
10375
],
[
10375,
57,
1213
]
],
[
[
480,
6,
3576
],
[
3576,
57,
1213
]
],
[
[
480,
21,
28882
],
[
28882,
60,
1213
]
],
[
[
480,
63,
1133
],
[
1133,
24,
1213
]
],
[
[
480,
24,
1619
],
[
1619,
63,
1213
]
],
[
[
480,
24,
688
],
[
688,
24,
1213
]
],
[
[
480,
62,
891
],
[
891,
24,
1213
]
],
[
[
480,
74,
1052
],
[
1052,
24,
1213
]
],
[
[
480,
23,
617
],
[
617,
24,
1213
]
]
] | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Formoterol",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Formoterol",
"{u} (Compound) binds {v} (Gene)",
"ADRB2"
],
[
"ADRB2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Formoterol",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Formoterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Formoterol",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Formoterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
]
] | Formoterol (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Dasatinib (Compound)
Formoterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is downregulated by Dasatinib (Compound)
Formoterol (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Formoterol may cause a minor interaction that can limit clinical effects when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Formoterol (Compound) resembles Ritodrine (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Formoterol may cause a minor interaction that can limit clinical effects when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib |
DB00741 | DB08907 | 167 | 1,344 | [
"DDInter885",
"DDInter280"
] | Hydrocortisone | Canagliflozin | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients . | Moderate | 1 | [
[
[
167,
24,
1344
]
],
[
[
167,
24,
549
],
[
549,
1,
1344
]
],
[
[
167,
6,
4973
],
[
4973,
45,
1344
]
],
[
[
167,
21,
28873
],
[
28873,
60,
1344
]
],
[
[
167,
25,
739
],
[
739,
24,
1344
]
],
[
[
167,
1,
1486
],
[
1486,
24,
1344
]
],
[
[
167,
63,
1523
],
[
1523,
24,
1344
]
],
[
[
167,
23,
1148
],
[
1148,
24,
1344
]
],
[
[
167,
24,
1150
],
[
1150,
24,
1344
]
],
[
[
167,
40,
870
],
[
870,
24,
1344
]
]
] | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Pancreatitis"
],
[
"Pancreatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Canagliflozin"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
],
[
"Guanethidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
]
] | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Hydrocortisone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Canagliflozin (Compound)
Hydrocortisone (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Canagliflozin (Compound)
Hydrocortisone may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Hydrocortisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine and Guanethidine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin |
DB00245 | DB00761 | 357 | 1,621 | [
"DDInter181",
"DDInter1497"
] | Benzatropine | Potassium chloride | Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970. The generation of structure-activity relationships proved that benztropine derivatives with the presence of a chlorine substituent in the para position in one of the phenyl rings produces an increased potency for dopamine uptake inhibition as well as a decreased inhibition of serotonin and norepinephrine. Benztropine was developed by USL Pharma and officially approved by the FDA on 1996. | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release dosage forms and those products formulated for preparation of solution prior to ingestion. | Major | 2 | [
[
[
357,
25,
1621
]
],
[
[
357,
21,
28929
],
[
28929,
60,
1621
]
],
[
[
357,
24,
13
],
[
13,
25,
1621
]
],
[
[
357,
1,
1443
],
[
1443,
64,
1621
]
],
[
[
357,
24,
100
],
[
100,
64,
1621
]
],
[
[
357,
35,
537
],
[
537,
64,
1621
]
],
[
[
357,
74,
352
],
[
352,
25,
1621
]
],
[
[
357,
35,
19
],
[
19,
25,
1621
]
],
[
[
357,
21,
28929
],
[
28929,
60,
803
],
[
803,
1,
1621
]
],
[
[
357,
21,
28704
],
[
28704,
60,
831
],
[
831,
24,
1621
]
]
] | [
[
[
"Benzatropine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Benzatropine",
"{u} (Compound) causes {v} (Side Effect)",
"Confusional state"
],
[
"Confusional state",
"{u} (Side Effect) is caused by {v} (Compound)",
"Potassium chloride"
]
],
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Benzatropine",
"{u} (Compound) resembles {v} (Compound)",
"Dimenhydrinate"
],
[
"Dimenhydrinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Benzatropine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Benzatropine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Benzatropine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Benzatropine",
"{u} (Compound) causes {v} (Side Effect)",
"Confusional state"
],
[
"Confusional state",
"{u} (Side Effect) is caused by {v} (Compound)",
"Calcium chloride"
],
[
"Calcium chloride",
"{u} (Compound) resembles {v} (Compound)",
"Potassium chloride"
]
],
[
[
"Benzatropine",
"{u} (Compound) causes {v} (Side Effect)",
"Flat affect"
],
[
"Flat affect",
"{u} (Side Effect) is caused by {v} (Compound)",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium chloride"
]
]
] | Benzatropine (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Potassium chloride (Compound)
Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may lead to a major life threatening interaction when taken with Potassium chloride
Benzatropine (Compound) resembles Dimenhydrinate (Compound) and Dimenhydrinate may lead to a major life threatening interaction when taken with Potassium chloride
Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may lead to a major life threatening interaction when taken with Potassium chloride
Benzatropine (Compound) resembles Cyclizine (Compound) and Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may lead to a major life threatening interaction when taken with Potassium chloride
Benzatropine (Compound) resembles Trospium (Compound) and Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may lead to a major life threatening interaction when taken with Potassium chloride
Benzatropine (Compound) resembles Hyoscyamine (Compound) and Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may lead to a major life threatening interaction when taken with Potassium chloride
Benzatropine (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Calcium chloride (Compound) and Calcium chloride (Compound) resembles Potassium chloride (Compound)
Benzatropine (Compound) causes Flat affect (Side Effect) and Flat affect (Side Effect) is caused by Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Potassium chloride |
DB00370 | DB13074 | 1,251 | 877 | [
"DDInter1230",
"DDInter1110"
] | Mirtazapine | Macimorelin | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. | Major | 2 | [
[
[
1251,
25,
877
]
],
[
[
1251,
23,
112
],
[
112,
23,
877
]
],
[
[
1251,
24,
1320
],
[
1320,
24,
877
]
],
[
[
1251,
63,
1101
],
[
1101,
24,
877
]
],
[
[
1251,
24,
485
],
[
485,
25,
877
]
],
[
[
1251,
25,
478
],
[
478,
25,
877
]
],
[
[
1251,
63,
1010
],
[
1010,
25,
877
]
],
[
[
1251,
25,
982
],
[
982,
64,
877
]
],
[
[
1251,
64,
702
],
[
702,
25,
877
]
],
[
[
1251,
23,
112
],
[
112,
23,
1247
],
[
1247,
23,
877
]
]
] | [
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Mirtazapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Macimorelin"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Mirtazapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Macimorelin"
]
]
] | Mirtazapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Macimorelin
Mirtazapine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Macimorelin
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may lead to a major life threatening interaction when taken with Macimorelin
Mirtazapine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Macimorelin
Mirtazapine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Macimorelin
Mirtazapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin |
DB00421 | DB11760 | 443 | 119 | [
"DDInter1707",
"DDInter1742"
] | Spironolactone | Talazoparib | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.[A11837, A178246] It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243, L6187] | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was approved by Health Canada in September 2020. Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306] | Moderate | 1 | [
[
[
443,
24,
119
]
],
[
[
443,
24,
971
],
[
971,
63,
119
]
],
[
[
443,
24,
1374
],
[
1374,
24,
119
]
],
[
[
443,
25,
1456
],
[
1456,
24,
119
]
],
[
[
443,
24,
971
],
[
971,
63,
1449
],
[
1449,
24,
119
]
],
[
[
443,
24,
1374
],
[
1374,
62,
441
],
[
441,
24,
119
]
],
[
[
443,
24,
578
],
[
578,
64,
441
],
[
441,
24,
119
]
],
[
[
443,
25,
1456
],
[
1456,
64,
1449
],
[
1449,
24,
119
]
],
[
[
443,
6,
4973
],
[
4973,
45,
1449
],
[
1449,
24,
119
]
],
[
[
443,
24,
1374
],
[
1374,
25,
985
],
[
985,
24,
119
]
]
] | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Spironolactone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simeprevir"
],
[
"Simeprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Spironolactone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simeprevir"
],
[
"Simeprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Spironolactone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Simeprevir"
],
[
"Simeprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
]
] | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Spironolactone may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Simeprevir and Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Spironolactone may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Simeprevir and Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Spironolactone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Simeprevir (Compound) and Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib |
DB00095 | DB00853 | 66 | 1,686 | [
"DDInter623",
"DDInter1762"
] | Efalizumab | Temozolomide | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML). | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably develop resistance to these agents over time.[A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow for both oral and intravenous administration.[A229853, A229888, A229923, L32033] Following initial hydrolysis, further reactions liberate a highly reactive methyl diazonium cation capable of methylating various residues on adenosine and guanine bases leading to DNA lesions and eventual apoptosis.[A229853, A229923] Temozomolide as an adjunct to radiotherapy followed by maintenance dosing remains the standard of care for both Glioblastoma and refractory anaplastic astrocytoma. Temozolomide was granted FDA approval on August 11, 1999, as an oral capsule and subsequently on February 27, 2009, as an intravenous injection. It is currently marketed under the trademark TEMODAR® by Merck. | Moderate | 1 | [
[
[
66,
24,
1686
]
],
[
[
66,
24,
970
],
[
970,
24,
1686
]
],
[
[
66,
24,
496
],
[
496,
63,
1686
]
],
[
[
66,
63,
1184
],
[
1184,
24,
1686
]
],
[
[
66,
23,
1461
],
[
1461,
24,
1686
]
],
[
[
66,
25,
1510
],
[
1510,
64,
1686
]
],
[
[
66,
24,
770
],
[
770,
64,
1686
]
],
[
[
66,
63,
581
],
[
581,
25,
1686
]
],
[
[
66,
25,
1066
],
[
1066,
25,
1686
]
],
[
[
66,
24,
970
],
[
970,
5,
11656
],
[
11656,
44,
1686
]
]
] | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
]
],
[
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
]
],
[
[
"Efalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Temozolomide"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Temozolomide"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Temozolomide"
]
],
[
[
"Efalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Temozolomide"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} (Compound) treats {v} (Disease)",
"skin cancer"
],
[
"skin cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Temozolomide"
]
]
] | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide
Efalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide
Efalizumab may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Temozolomide
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Temozolomide
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Temozolomide
Efalizumab may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Temozolomide
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil (Compound) treats skin cancer (Disease) and skin cancer (Disease) is treated by Temozolomide (Compound) |
DB00758 | DB01229 | 1,347 | 973 | [
"DDInter413",
"DDInter1377"
] | Clopidogrel | Paclitaxel | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease, It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin. Clopidogrel was granted FDA approval on 17 November 1997. | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. | Moderate | 1 | [
[
[
1347,
24,
973
]
],
[
[
1347,
6,
7524
],
[
7524,
45,
973
]
],
[
[
1347,
7,
2903
],
[
2903,
46,
973
]
],
[
[
1347,
18,
5360
],
[
5360,
46,
973
]
],
[
[
1347,
18,
4677
],
[
4677,
57,
973
]
],
[
[
1347,
21,
28643
],
[
28643,
60,
973
]
],
[
[
1347,
63,
307
],
[
307,
23,
973
]
],
[
[
1347,
24,
68
],
[
68,
63,
973
]
],
[
[
1347,
62,
362
],
[
362,
24,
973
]
],
[
[
1347,
25,
1213
],
[
1213,
63,
973
]
]
] | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Clopidogrel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Clopidogrel",
"{u} (Compound) upregulates {v} (Gene)",
"MMP1"
],
[
"MMP1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Clopidogrel",
"{u} (Compound) downregulates {v} (Gene)",
"PDIA5"
],
[
"PDIA5",
"{u} (Gene) is upregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Clopidogrel",
"{u} (Compound) downregulates {v} (Gene)",
"RFC2"
],
[
"RFC2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Clopidogrel",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
]
] | Clopidogrel (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paclitaxel (Compound)
Clopidogrel (Compound) upregulates MMP1 (Gene) and MMP1 (Gene) is upregulated by Paclitaxel (Compound)
Clopidogrel (Compound) downregulates PDIA5 (Gene) and PDIA5 (Gene) is upregulated by Paclitaxel (Compound)
Clopidogrel (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is downregulated by Paclitaxel (Compound)
Clopidogrel (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Paclitaxel (Compound)
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin and Troleandomycin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Clopidogrel may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel |
DB01041 | DB06288 | 770 | 607 | [
"DDInter1789",
"DDInter77"
] | Thalidomide | Amisulpride | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of a different drug class. It is marketed under the brand name Barhemsys. | Moderate | 1 | [
[
[
770,
24,
607
]
],
[
[
770,
21,
29232
],
[
29232,
60,
607
]
],
[
[
770,
63,
112
],
[
112,
23,
607
]
],
[
[
770,
63,
1559
],
[
1559,
24,
607
]
],
[
[
770,
64,
589
],
[
589,
24,
607
]
],
[
[
770,
25,
1019
],
[
1019,
63,
607
]
],
[
[
770,
24,
1662
],
[
1662,
63,
607
]
],
[
[
770,
24,
351
],
[
351,
64,
607
]
],
[
[
770,
24,
401
],
[
401,
25,
607
]
],
[
[
770,
63,
1166
],
[
1166,
25,
607
]
]
] | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Thalidomide",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amisulpride"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amisulpride"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
]
] | Thalidomide (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Amisulpride (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Amisulpride
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride
Thalidomide may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride
Thalidomide may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Amisulpride
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Amisulpride
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Amisulpride |
DB01115 | DB09143 | 336 | 313 | [
"DDInter1291",
"DDInter1701"
] | Nifedipine | Sonidegib | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981. | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Moderate | 1 | [
[
[
336,
24,
313
]
],
[
[
336,
62,
1194
],
[
1194,
23,
313
]
],
[
[
336,
24,
478
],
[
478,
24,
313
]
],
[
[
336,
23,
578
],
[
578,
24,
313
]
],
[
[
336,
24,
484
],
[
484,
63,
313
]
],
[
[
336,
63,
752
],
[
752,
24,
313
]
],
[
[
336,
25,
129
],
[
129,
25,
313
]
],
[
[
336,
63,
600
],
[
600,
25,
313
]
],
[
[
336,
24,
1040
],
[
1040,
25,
313
]
],
[
[
336,
24,
283
],
[
283,
64,
313
]
]
] | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Nifedipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sonidegib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Nifedipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Nifedipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
]
] | Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Nifedipine may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Sonidegib
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Sonidegib
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may lead to a major life threatening interaction when taken with Sonidegib
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Sonidegib |
DB00704 | DB00899 | 267 | 411 | [
"DDInter1263",
"DDInter1579"
] | Naltrexone | Remifentanil | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia. | Major | 2 | [
[
[
267,
25,
411
]
],
[
[
267,
25,
1322
],
[
1322,
40,
411
]
],
[
[
267,
25,
704
],
[
704,
1,
411
]
],
[
[
267,
64,
1349
],
[
1349,
40,
411
]
],
[
[
267,
6,
6591
],
[
6591,
45,
411
]
],
[
[
267,
21,
29231
],
[
29231,
60,
411
]
],
[
[
267,
64,
475
],
[
475,
24,
411
]
],
[
[
267,
63,
1648
],
[
1648,
24,
411
]
],
[
[
267,
40,
173
],
[
173,
63,
411
]
],
[
[
267,
25,
407
],
[
407,
63,
411
]
]
] | [
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Remifentanil"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alfentanil"
],
[
"Alfentanil",
"{u} (Compound) resembles {v} (Compound)",
"Remifentanil"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound)",
"Remifentanil"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meperidine"
],
[
"Meperidine",
"{u} (Compound) resembles {v} (Compound)",
"Remifentanil"
]
],
[
[
"Naltrexone",
"{u} (Compound) binds {v} (Gene)",
"OPRM1"
],
[
"OPRM1",
"{u} (Gene) is bound by {v} (Compound)",
"Remifentanil"
]
],
[
[
"Naltrexone",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Remifentanil"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
]
],
[
[
"Naltrexone",
"{u} (Compound) resembles {v} (Compound)",
"Naloxone"
],
[
"Naloxone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
]
],
[
[
"Naltrexone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
]
]
] | Naltrexone may lead to a major life threatening interaction when taken with Alfentanil and Alfentanil (Compound) resembles Remifentanil (Compound)
Naltrexone may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl (Compound) resembles Remifentanil (Compound)
Naltrexone may lead to a major life threatening interaction when taken with Meperidine and Meperidine (Compound) resembles Remifentanil (Compound)
Naltrexone (Compound) binds OPRM1 (Gene) and OPRM1 (Gene) is bound by Remifentanil (Compound)
Naltrexone (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Remifentanil (Compound)
Naltrexone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil
Naltrexone (Compound) resembles Naloxone (Compound) and Naloxone may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil
Naltrexone may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil |
DB00877 | DB01229 | 629 | 973 | [
"DDInter1678",
"DDInter1378"
] | Sirolimus | Paclitaxel (protein-bound) | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
629,
24,
973
]
],
[
[
629,
24,
310
],
[
310,
63,
973
]
],
[
[
629,
6,
7524
],
[
7524,
45,
973
]
],
[
[
629,
7,
9489
],
[
9489,
46,
973
]
],
[
[
629,
18,
3702
],
[
3702,
46,
973
]
],
[
[
629,
18,
4677
],
[
4677,
57,
973
]
],
[
[
629,
7,
9440
],
[
9440,
57,
973
]
],
[
[
629,
21,
29267
],
[
29267,
60,
973
]
],
[
[
629,
63,
307
],
[
307,
23,
973
]
],
[
[
629,
63,
134
],
[
134,
24,
973
]
]
] | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Sirolimus",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Sirolimus",
"{u} (Compound) upregulates {v} (Gene)",
"WIF1"
],
[
"WIF1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Sirolimus",
"{u} (Compound) downregulates {v} (Gene)",
"TP53BP2"
],
[
"TP53BP2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Sirolimus",
"{u} (Compound) downregulates {v} (Gene)",
"RFC2"
],
[
"RFC2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Sirolimus",
"{u} (Compound) upregulates {v} (Gene)",
"CRTAP"
],
[
"CRTAP",
"{u} (Gene) is downregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Sirolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Alanine aminotransferase increased"
],
[
"Alanine aminotransferase increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
]
] | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Sirolimus (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paclitaxel (Compound)
Sirolimus (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Paclitaxel (Compound)
Sirolimus (Compound) downregulates TP53BP2 (Gene) and TP53BP2 (Gene) is upregulated by Paclitaxel (Compound)
Sirolimus (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is downregulated by Paclitaxel (Compound)
Sirolimus (Compound) upregulates CRTAP (Gene) and CRTAP (Gene) is downregulated by Paclitaxel (Compound)
Sirolimus (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Paclitaxel (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel |
DB00193 | DB00434 | 534 | 13 | [
"DDInter1841",
"DDInter459"
] | Tramadol | Cyproheptadine | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of [morphine]. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as [dul | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
534,
24,
13
]
],
[
[
534,
25,
104
],
[
104,
63,
13
]
],
[
[
534,
24,
537
],
[
537,
63,
13
]
],
[
[
534,
6,
2720
],
[
2720,
45,
13
]
],
[
[
534,
18,
8800
],
[
8800,
46,
13
]
],
[
[
534,
18,
4187
],
[
4187,
57,
13
]
],
[
[
534,
21,
28905
],
[
28905,
60,
13
]
],
[
[
534,
24,
352
],
[
352,
24,
13
]
],
[
[
534,
40,
506
],
[
506,
63,
13
]
],
[
[
534,
25,
999
],
[
999,
24,
13
]
]
] | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"CHRM3"
],
[
"CHRM3",
"{u} (Gene) is bound by {v} (Compound)",
"Cyproheptadine"
]
],
[
[
"Tramadol",
"{u} (Compound) downregulates {v} (Gene)",
"RBM34"
],
[
"RBM34",
"{u} (Gene) is upregulated by {v} (Compound)",
"Cyproheptadine"
]
],
[
[
"Tramadol",
"{u} (Compound) downregulates {v} (Gene)",
"EIF4EBP1"
],
[
"EIF4EBP1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Cyproheptadine"
]
],
[
[
"Tramadol",
"{u} (Compound) causes {v} (Side Effect)",
"Irritability"
],
[
"Irritability",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cyproheptadine"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Tramadol",
"{u} (Compound) resembles {v} (Compound)",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
]
] | Tramadol may lead to a major life threatening interaction when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Tramadol (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Cyproheptadine (Compound)
Tramadol (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is upregulated by Cyproheptadine (Compound)
Tramadol (Compound) downregulates EIF4EBP1 (Gene) and EIF4EBP1 (Gene) is downregulated by Cyproheptadine (Compound)
Tramadol (Compound) causes Irritability (Side Effect) and Irritability (Side Effect) is caused by Cyproheptadine (Compound)
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Tramadol (Compound) resembles Dextromethorphan (Compound) and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Tramadol may lead to a major life threatening interaction when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine |
DB00344 | DB01166 | 1,302 | 477 | [
"DDInter1543",
"DDInter379"
] | Protriptyline | Cilostazol | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, alpha<sub>1</sub | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Moderate | 1 | [
[
[
1302,
24,
477
]
],
[
[
1302,
6,
12523
],
[
12523,
45,
477
]
],
[
[
1302,
18,
16896
],
[
16896,
57,
477
]
],
[
[
1302,
21,
28658
],
[
28658,
60,
477
]
],
[
[
1302,
23,
112
],
[
112,
23,
477
]
],
[
[
1302,
24,
126
],
[
126,
23,
477
]
],
[
[
1302,
24,
820
],
[
820,
63,
477
]
],
[
[
1302,
24,
888
],
[
888,
24,
477
]
],
[
[
1302,
1,
109
],
[
109,
24,
477
]
],
[
[
1302,
25,
1133
],
[
1133,
24,
477
]
]
] | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Protriptyline",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Cilostazol"
]
],
[
[
"Protriptyline",
"{u} (Compound) downregulates {v} (Gene)",
"IARS2"
],
[
"IARS2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Cilostazol"
]
],
[
[
"Protriptyline",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cilostazol"
]
],
[
[
"Protriptyline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Protriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
]
] | Protriptyline (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Cilostazol (Compound)
Protriptyline (Compound) downregulates IARS2 (Gene) and IARS2 (Gene) is downregulated by Cilostazol (Compound)
Protriptyline (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Cilostazol (Compound)
Protriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Protriptyline (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Protriptyline may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol |
DB00398 | DB09104 | 79 | 286 | [
"DDInter1702",
"DDInter1118"
] | Sorafenib | Magnesium hydroxide | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). | Moderate | 1 | [
[
[
79,
24,
286
]
],
[
[
79,
24,
820
],
[
820,
23,
286
]
],
[
[
79,
63,
1252
],
[
1252,
23,
286
]
],
[
[
79,
24,
859
],
[
859,
24,
286
]
],
[
[
79,
64,
494
],
[
494,
24,
286
]
],
[
[
79,
25,
1593
],
[
1593,
24,
286
]
],
[
[
79,
63,
1181
],
[
1181,
24,
286
]
],
[
[
79,
24,
730
],
[
730,
63,
286
]
],
[
[
79,
25,
982
],
[
982,
63,
286
]
],
[
[
79,
23,
809
],
[
809,
25,
286
]
]
] | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
],
[
"Deutetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Sorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Raltegravir"
],
[
"Raltegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Magnesium hydroxide"
]
]
] | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Sorafenib may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Sorafenib may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine and Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Sorafenib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Raltegravir and Raltegravir may lead to a major life threatening interaction when taken with Magnesium hydroxide |
DB01281 | DB10429 | 881 | 200 | [
"DDInter5",
"DDInter282"
] | Abatacept | Candida albicans | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077). | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
881,
24,
200
]
],
[
[
881,
24,
1683
],
[
1683,
24,
200
]
],
[
[
881,
25,
976
],
[
976,
24,
200
]
],
[
[
881,
64,
1377
],
[
1377,
24,
200
]
],
[
[
881,
63,
1184
],
[
1184,
24,
200
]
],
[
[
881,
24,
270
],
[
270,
63,
200
]
],
[
[
881,
25,
1583
],
[
1583,
63,
200
]
],
[
[
881,
24,
1683
],
[
1683,
63,
1096
],
[
1096,
24,
200
]
],
[
[
881,
25,
976
],
[
976,
64,
1096
],
[
1096,
24,
200
]
],
[
[
881,
64,
1377
],
[
1377,
64,
1096
],
[
1096,
24,
200
]
]
] | [
[
[
"Abatacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Abatacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Abatacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Abatacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Abatacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
]
] | Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Abatacept may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Abatacept may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Abatacept may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Abatacept may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Abatacept may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans |
DB01169 | DB11730 | 57 | 351 | [
"DDInter120",
"DDInter1588"
] | Arsenic trioxide | Ribociclib | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Major | 2 | [
[
[
57,
25,
351
]
],
[
[
57,
62,
1247
],
[
1247,
23,
351
]
],
[
[
57,
63,
479
],
[
479,
23,
351
]
],
[
[
57,
63,
355
],
[
355,
24,
351
]
],
[
[
57,
64,
827
],
[
827,
24,
351
]
],
[
[
57,
25,
1491
],
[
1491,
24,
351
]
],
[
[
57,
24,
657
],
[
657,
24,
351
]
],
[
[
57,
25,
129
],
[
129,
25,
351
]
],
[
[
57,
64,
1585
],
[
1585,
25,
351
]
],
[
[
57,
25,
1297
],
[
1297,
64,
351
]
]
] | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trazodone"
],
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
],
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Adenosine"
],
[
"Adenosine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
]
] | Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Arsenic trioxide may lead to a major life threatening interaction when taken with Trazodone and Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Arsenic trioxide may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Arsenic trioxide may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ribociclib
Arsenic trioxide may lead to a major life threatening interaction when taken with Adenosine and Adenosine may lead to a major life threatening interaction when taken with Ribociclib
Arsenic trioxide may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may lead to a major life threatening interaction when taken with Ribociclib |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.